|
| CMP-0001-26 | 01/01/2026 | RA | Permanent | Major | Overprinting of QR matrix code, GTIN number and Serial Number on unit cartons of Pharmaceutical products exporting in Uzbekistan and implementation of aggregation process. | Currently, products exporting to Uzbekistan only contain batch number, manufacturinng date and expiry date on finished product. | 1) It is proposed to carry out overprinting of QR matrix codes, GTIN numbers, and serial numbers on the unit cartons of pharmaceutical products intended for export to Uzbekistan as per following information.
The QR matrix code will contain specific product and serialization information. This data will provided by our partner in Uzbekistan in the form of an excel sheet. The data in the sheet will be converted in the form of data matrix codes. The information will be unique to each individual unit carton and will be shared by the partner separately for each upcoming order destined for the Uzbekistan market.
GTIN number: (Already provided by PharmEvo to partner and will be included in the excel sheet shared by partner)
Serial Number: (Will be provided by partner)
Individual Sequence number: (Will be provided by partner)
Verification code: (Will be provided by partner)
While following information will be printed in human readable form in the following format:
GTIN:
BATCH NO:
MFG:
EXP:
SN:
2) Aggregation process will be implemented for all pharmaceutical products exporting in Uzbekistan. | N/A | Approved | 31/05/2026 | In Progress | Pharma | 1) Serial number, individual sequence number and verification codes required for printing on each unit carton of Uzbekistan order products. (RA)
2) Excel sheet data will be integrated with the PharmaTrax software for code management. (RA)
3) Tertiary packaging (Master carton) label will be generated through pharmatrax software containing all information on unit carton. (RA & Production)
4) Software verification will be performed. QA (Val)
5) Instruction will be incorporate in EPO. (SCM)
6) For every upcoming order for Uzbekistan SCM will inform immediately to RA for the issuance of verification code/ Information in password protected excel sheet. (SCM & RA)
07) SOP to be developed for QR code management for the Uzbekistan. (RA)
08) SOP for the pharmatrax software will be revised to include operation and reconciliation of codes. (Production)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Jan-26
02) Jan-26
03) Jan-26
04) Feb-26
05) Feb-26
06) Jan-26
07) May-26 (Extension till Dec-26)
08) May-26 (Extension till Dec-26)
| Hamza Ahmed | 01/01/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0002-26 | 01/01/2026 | QC | Temporary | Minor | Due to malfunction observed in the IR system within the QC department, IR based identification testing is temporarily unavailable. | Currently, there is a malfunctioning observed in the IR equipment within the QC department, which is preventing the release of materials. | All raw materials will be released using alternative identification methods until the IR equipment is operational. | N/A | Approved | 28/02/2026 | Closed | Pharma | 01) Vendor inspection report required. (QC)
02) Alternate ID test will be perform for raw materials. (QC)
03) Performance Qualification will be perform after the IR system is operational. (QC)
| 01) Done
02) Done
03) Done
| 01) Feb-26
02) Feb-26
03) Feb-26
| Hamza Ahmed | 01/01/2026 | Muhammad Haris | 18/03/2026 |
|
| CMP-0003-26 | 07/01/2026 | QC | Permanent | Moderate | Sampling of Nutraceutical APIs will be carried out as per vN +1 rule. | Currently, sampling of nutraceutical APIs is performed on 100% of containers for identification. | It is proposed that sampling of all nutraceutical APIs will be carried out in accordance with the vN +1 rule. | N/A | Approved | 31/03/2026 | Closed | Pharma | 1) SOP will be developed. (QC)
2) Training will be provided to concern person. (QC)
| 01) Done
02) Done
| 01) March-26
02) March-26
| Hamza Ahmed | 07/01/2026 | Muhammad Haris | 07/05/2026 |
|
| CMP-0004-26 | 07/01/2026 | SCM | Permanent | Major | Alternate source induction for Empty Shell Hard Gelatin Capsule Size 0,1 & 2. | We are currently purchasing Empty Hard Gelatin Capsules Size 0,1 & 2 from M/s Health Capsules Pakistan Add: P-25, Phase 1-A, Sahiawala Industrial Estate, FIEDMC, Faisalabad | It is proposed to induct one more source M/s. PharmNova Pvt Ltd. located at Plot # 154 & 93, Deh Kanto Tappo, Landhi Bin Qasim, Karachi | N/A | Approved | 31/12/2026 | In Progress | Pharma | 1) Source approval document will be submitted to QA. (SCM)
2) Procurement of material from new source. (SCM)
3) Vendor list will be updated. (QA)
4) Source name will be added in SAP. (QC)
5) Process validation will be performed. QA(Val)
6) Stability will be performed on validation batches. (QC)
| 01) Done
02) Done
03) Done
04) Done
| 01) Jan-26
02) Jan-26
03) Feb-26
04) Done
05) Dec-26
06) Dec-26
| Hamza Ahmed | 08/01/2026 | Muhammad Haris | 11/03/2026 |
|
| CMP-0005-26 | 08/01/2026 | BD | Permanent | Minor | Revision of Zi-AD Syrup Label (5mg/5ml). | The currently approved label dimensions for Zi-AD Syrup are not compatible with the 60ml PET bottle dimensions.
Existing label dimensions: 50mmx85mm. | Revision of label dimension inline with 60ml PET bottle dimensions.
Proposed Label Dimensions: 50mmx85mm | N/A | Approved | 31/03/2026 | Closed | Pharma | 01) Artwork will be developed. (BD)
02) Item code will be open. (BD)
03) Existing inventory will be write off. (SCM)
04) Old item code will be block for procurement. (SCM)
05) BOM will be revise in SAP. (QA)
06) PO will be revise. (QA)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Done
02) Done
03) Done
04) Done
05) March-26
06) March-26
| Hamza Ahmed | 08/01/2026 | Muhammad Haris | 13/05/2026 |
|
| CMP-0006-26 | 13/01/2026 | BD | Permanent | Moderate | Revision of GTM artworks as per EXGP-S. | Currently, all products commercialized in Guatemala are assigned country-specific finished goods (FG) and packaging (PKG) codes. The artworks are also country-specific. | Existing artworks will be revised to allign with EXGP-S requirement. The current orders will be processed using the existing Guatemala-specific FG codes with new EXGP-S Artwork. New orders will be subsequently placed using FG codes in accordance with EXGP-S | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Notification required from ministry. (RA)
02) Development and approval of artwork. (BD)
03) Item code will be open. (BD)
04) FG code will be open. (SCM)
05) Existing inventory will be write off. (SCM)
06) Old item code will be block for procurement. (SCM)
07) BOM will create in SAP. (QA)
08) BPR will be prepared. (QA)
09) Procurement of packaging material. (SCM)
10) Specification will be updated in SAP. (QC)
|
| 01) June-26
02) June-26
03) June-26
04) June-26
05) June-26
06) June-26
07) June-26
08) June-26
09) June-26
10) Aug-26
| Hamza Ahmed | 13/01/2026 | Muhammad Haris | 18/03/2026 |
|
| CMP-0007-26 | 13/01/2026 | PD | Permanent | Major | Change in Formulation of Finerdia 10mg tablet & Finerdia 20mg tablet. | 1. The product is currently manufactured as per the formulation in Annexure-1
2. Currently Opadry White 03F580033 is being utilized in the formulation. | 1. The proposed formulation is qualitatively similar to the existing but differs quantitatively as mentioned in annexure-1.
2. Replacing Opadry White 03F580033 with sheffcoat PVA White to improve the physical appearance of tablet. | RA-0003-26-P | Approved | 30/04/2026 | Closed | Pharma | 01) PD trial is required. (PD)
02) SFG BOM will be revise in SAP. (QA)
03) BDR & BMR will be revise. (QA)
04) Routing will be created in SAP. (Prod)
05) Process Validation will be performed. QA(Val)
06) Stability will be performed on validation batches. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Done
02) Jan-26
03) Jan-26
04) Jan-26
05) April-26 (Extension till June-26)
06) April-26 (Extension till June-26)
| Hamza Ahmed | 13/01/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0008-26 | 13/01/2026 | Engineering | Permanent | Moderate | Installation of non-returnable valves at all points of compressed air in the production area. | Currently, ball valve are install at compressed air point of use total 31 valves are served in the production areas. | It is proposed to installed non return valves at compressed air point of use in order to compliant with GMP requirement. | N/A | Approved | 31/03/2026 | Closed | Pharma | 01) Installation of non-return valves at all points of compressed air. (Engineering)
02) Inspection of non-return valves will be added in current preventive maintenance program. (Engineering)
03) Chemical testing of product contact point will be perform. QC & QA (Val)
04) Micro testing of product contact point will be perform. QC (Micro)
05) Compressed air layout need to be developed with IDs. (Engineering)
| 01) Done
02) Done
03) Done
04) Done
05) Done
| 01) Feb-26
02) Feb-26
03) March-26
04) Feb-26
05) Feb-26
| Hamza Ahmed | 13/01/2026 | Muhammad Haris | 09/05/2026 |
|
| CMP-0009-26 | 13/01/2026 | QA | Permanent | Moderate | Change in Batch Numbering System for Pharma and Nutra products. | Currently, batch numbering system for pharma products consist of five alphanumeric characters.(i.e. 6A001) and for nutra batch numbering system consist of six alphanumeric characters.(i.e. N6A001).
For Pharma:
B.No =6A001
First letter “6” represents the year
2nd letter “A” represents the month of dispensing
Last three letters “001”Serial number of batches in a month.
For Nutra:
B.No =N6A001
First letter “N” represents the nutra
2nd letter “6” represents the year
3rd letter “A”represents the month of dispensing
Last three letters “001” serial number of batches in a month. | It is proposed to change the batch numbering system for pharma products to six Alphanumeric characters.(i.e. 26A001) and for nutra batch numbering system to seven alphanumeric
characters.(i.e. N26A001).
For Pharma:
B.No =26A001
First two letter “26” represents the year
3rd letter “A” represents the month of dispensing
Last three letters “001”Serial number of batches in a month.
For Nutra:
B.No =N26A001
First letter “N” represents the nutra
2nd and 3rd letter “26” represents the year
4th letter represents the month of dispensing
Last three letters 001=Serial number of batches in a month. | RA-0004-26-P | Under Approval | | Closed | Pharma |
| Closed without implementation.
|
| Hamza Ahmed | 13/01/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0010-26 | 15/01/2026 | BD | Permanent | Moderate | Revision in PS Unit Carton Dimensions for Emglin 25mg Tablets- Central America. | Current;y, the dimensions of the U/C are not adequate to accommodate the Direction Insert (DI). Existing U/C Dimension: 85mmx60mmx15mm. | The U/C dimensions of Emglin 25mg Tablet (PS) will be revised to align with the size requirements of the Direction Insert (DI).
Proposed U/C Dimension: 95mmx70mmx20mm. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) Existing inventory will be write off. (SCM)
04) Old item code will be block for procurement. (SCM)
05) BOM will be create in SAP. (QA)
06) BPR will be prepared. (QA)
07) Procurement of packaging material. (SCM)
08) Specification will be updated in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
07) Done
08) Done
| 01) Done
02) Done
03) Feb-26
04) Feb-26
05) Mar-26
06) Mar-26
07) April-26
08) April-26
| Hamza Ahmed | 15/01/2026 | Muhammad Haris | 30/06/2026 |
|
| CMP-0011-26 | 16/01/2026 | Production | Permanent | Major | Transfer of export group A (EXGP-A) products to Hoonga blister machine. | The products mentioned on the attached list are currently being blistered on BM-350 blister machine (List attached). | The products mentioned on the attached list are agreed to move to the Hoonga Blister Machine. (list attached) | RA-0006-26-P | Approved | 31/12/2027 | In Progress | Pharma | 01) Annual notification will be applied in Nigeria and Ghana. (RA)
02) Variation will be applied in Kenya and French West African countries before implementation. (RA)
03) Approval is required for additional pack size in export countries before implementation. (RA)
04) Artwork will be develop as per Hoonga Blister Machine. (BD)
05) Item code will be open. (BD)
06) Procurement of packaging material. (SCM)
07) Existing inventory will be consume. (SCM)
08) BOM will be revise in SAP. (QA)
09) BPR will be revise. (QA)
10) Process validation will be perform by matrixing approach. QA (Val)
11) Specification will be updated in SAP. (QC)
|
| 01) June-26
02) Sep-26
03) Sep-26
04) Jan-27
05) Jan-27
06) June-27
07) June-27
08) Aug-27
09) Aug-27
10) Dec-27
11) Dec-27
| Hamza Ahmed | 16/01/2026 | Muhammad Haris | 17/06/2026 |
|
| CMP-0012-26 | 16/01/2026 | QC | Temporary | Minor | Temporary use of QC ceph lab UV spectrophotometer for QC general pharma testing. | The UV spectrophotometer (UV-01) installed in the QC General Pharma area is out of order. Therefore, batches requiring UV analysis are currently pending at QC testing. | It is proposed that samples to be prepared in the QC General Pharma area and then sent to the QC Ceph Lab for performing the UV analysis. The samples will be discarded in the Ceph lab after analysis to avoid cross-contamination. Documents (UV report) will be shared via email. All the raw data and other documents will be maintained in General Pharma QC Lab. | N/A | Approved | 31/01/2026 | Closed | Pharma | 01) Vendor will be called for instrument maintenance. (QC)
02) Field service report will be provided. (QC)
| 01) Done
02) Done
| 01) Jan-26
02) Jan-26
| Hamza Ahmed | 16/01/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0013-26 | 16/01/2026 | SCM | Permanent | Moderate | Institution order of MCC KPK. | Order of MCC KPK is received from institution market. | We have reviewed order of following products from MCC KPK.
01) BOM code: BOM code required. Product: Cap Zoltar 40mg. Material Status: AF need to be develope. Order Qty: 145,000. Institute: MCC KPK Supplies 2025-26.
02) BOM code: BOM code required. Product: Tab Tansin 50mg. Material Status: AF need to be develope. Order Qty: 90,000. Institute: MCC KPK Supplies 2025-26.
03) BOM code: BOM code required. Product: Tab Zilfom 400mg. Material Status: AF need to be develope. Order Qty: 52,000. Institute: MCC KPK Supplies 2025-26.
04) BOM code: BOM code required. Product: Tab Evopride 2mg. Material Status: AF need to be develope. Order Qty: 10,500. Institute: MCC KPK Supplies 2025-26.
05) BOM code: BOM code required. Product: Tab Aireez 10mg. Material Status: AF need to be develope. Order Qty: 10,000. Institute: MCC KPK Supplies 2025-26.
For Aluminium Foil:
Base color in green with stamp of "GOVERNMENT OF KHYBER PAKHTUNKHWA MCC SUPPLY- NOT FOR SALE".
Commercial Packs with stamp of "GOVERNMENT OF KHYBER PAKHTUNKHWA MCC SUPPLY- NOT FOR SALE". | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) BOM will be created in SAP. (QA)
05) BPR will be prepared. (QA)
06) Specification will be updated in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Done
02) Done
03) Done
04) Feb-26
05) March-26
06) April-26
| Hamza Ahmed | 16/01/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0014-26 | 16/01/2026 | QA | Permanent | Major | Change of PW loop temperature from 80ºC to ambient temperature (25-30ºC). | Currently Purified water is continuously circulated in loop at 80ºC (±5ºC).
| It is proposed to reduce temperature of purified water loop to ambient temperature (25-30ºC). However, due to this purpose change sanitization frequency need to be defined and qualification of purified water system loop will be performed. | RA-0001-26-P | Approved | 31/12/2026 | In Progress | Pharma | 1) Qualification will be performed (validation)
2) Dead leg study will be performed (Engineering)
3) Cleaning procedure with ambient water temperature will be checked for cleaning effectiveness (PD)
4) SOP for sanitization of purified water tank and loop (ENG/2/101) will be revised (Engineering)
5) SOP for "operation of purified water loop heat exchanger" (ENO/2/134) will be obsoleted (engineering)
6) SOP for cleaning of utensils (scoops, spoons, measuring cylinder and sampling thives used in warehouse (WHG/2/033) will be revised. (warehouse)
7) All relevant SOPs of production for cleaning with purified water will be revised to change temperature from 80C to ambient (production)
|
| 01) Sep-26
02) Sep-26
03) Sep-26
04) Sep-26
05) Sep-26
06) Sep-26
07) Dec-26
| Hamza Ahmed | 16/01/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0015-26 | 21/01/2026 | SCM | Temporary | Moderate | Over printing of suffix with batch number for the identification of different shelf life in same batch. | The Products(s) and Batch(es) has already been packed & invociesd as per procedure for export in FWA region. | We need to over print batch. no with mentioning the suffix for identification of different shelf life in sam batch (i.e 24 months(s) and 36 months(s)).
Details of products with complete details is attached. | N/A | Approved | 31/01/2026 | Closed | Pharma | 01) For products distributed in different countries under the same batch number but with different shelf life then suffix "A" will be printed with the batch number for those products whose shelf life is 36 months.
02) COA will be prepared. (QC)
03) Batch Release Certificate will be prepared. (QA)
| 01) Done
02) Done
03) Done
| 01) Jan-26
02) Jan-26
03) Jan-26
| Hamza Ahmed | 21/01/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0016-26 | 22/01/2026 | QA | Permanent | Moderate | To implement microbiological assay testing on every batch of Cephalosporin suspension products. | Previously micro testing was performed on every tenth batch of Cephalosporin suspension products. | It is proposed to conduct micro testing on every batch of Cephalosporin suspension products. | N/A | Approved | 31/01/2026 | Closed | Pharma | 01) SOP for "Microbiological Enumeration and Specified Micro-organisms Detection in Finished Products" (QCM/2/041) will be revise. QC(Micro).
02) Training will be provided to concern person. QC(Micro)
| 01) Done
02) Done
| 01) Jan-26
02) Jan-26
| Hamza Ahmed | 22/01/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0017-26 | 22/01/2026 | QC | Permanent | Major | Procurement & Induction of a new semi micro balance Mettler Toledo Model: MA55. | Semi-Micro balance XSR105DU (Asset No. 1500000865) has experienced a critical hardware malfunction. The balance has been sent to the Vendor (Rauf Electronics) for diagnosis. Diagnosis indicates the failure of HMI device. | Semi-Micro balance XSR105DU (Asset No. 1500000865) will be traded off to Vendor (Rauf Electronics) for a new semi micro balance (Model: MA55). New equipment ID and asset number will be allotted as per procedure. | RA-0005-26-P | Approved | 31/08/2026 | In Progress | Pharma | 1) Asset trade form to be generated. (QC)
2) CAPEX of new semi micro balance to be generated. (QC)
03) IQ and OQ will be perform. (QC)
04) SOP will be prepared. (QC)
05) PQ will be perform. QA(Val)
06) Instrument list will be updated. (QC)
07) Calibration list will be updated. QA(Val)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Feb-26
02) March-26
03) July-26
04) July-26
05) July-26
06) July-26
07) Aug-26
| Hamza Ahmed | 22/01/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0018-26 | 23/01/2026 | Production | Permanent | Major | Tranferring of products to Hoonga Blister Machine Local CP | The products mentioned on the attached list are currently being blistered on 2DT blister machine as per mentioned dimensions (list attached). A/F 170mm & CFF 175mm. (List attached) | The Products mentioned on the attached list are agreed to move to the Hoonga Blister Machine as per mentioned dimensions (list attached). A/F 288mm & CFF 290mm. | RA-0006-26-P | Approved | 30/04/2027 | In Progress | Pharma | 01) Intimation to be submitted in DRAP. (RA)
02) Development and approval of artwork. (BD)
03) New item codes will be open. (BD)
04) Existing inventory will be consume. (SCM)
05) Procurement of packaging material. (SCM)
06) New tooling will be required. (Prod)
07) BOM will be revise in SAP. (QA)
08) BPR will be revise. (QA)
09) Process validation will be performed on blistering stage. QA(Val)
10) Specification will be update in SAP. (QC)
|
| 01) Dec-26
02) Nov-26
03) Nov-26
04) Dec-26
05) Nov-26
06) Oct-26
07) Dec-26
08) Dec-26
09) April-27
10) Dec-26
| Hamza Ahmed | 23/01/2026 | Muhammad Haris | 01/08/2026 |
|
| CMP-0019-26 | 23/01/2026 | SCM | Permanent | Minor | Change in Manufacturer name | We have approved manufacturer by the name of M/s. Venkata Narayana Active Ingredients Private Limited.
Address: Sy. No.69, Chandrapadiya Village, Vinjamur Mandal, S.P.S.R. Nellore District-524 228. Andhra Pradesh. | It is to proposed that manufacturer name has been changed to M/s. Chieron Active Ingredients Pvt. Ltd. Address: While the manufacturer site/material will remain same. | N/A | Approved | 31/03/2026 | Closed | Pharma | 01) Vendor list will be updated. (QA)
02) Vendor name will be updated in SAP. (QC)
| 01) Done
02) Done
| 01) March-26
02) March-26
| Hamza Ahmed | 23/01/2026 | Muhammad Haris | 07/05/2026 |
|
| CMP-0020-26 | 30/01/2026 | SCM | Permanent | Major | Change of Name and manufacturing site for API Manufacturer M/S PRUDENCE PHARMA CHEM | We are currently procuring APIs Amlodipine Besylate, Febuxostat, Glimepiride from M/S PRUDENCE PHARMA CHEM located at Plot no. 7407, GIDC Estate, Ankleshwar- 393002, Bharuch, Gujarat, India. | Now manufacturer has changed their name to M/S Pridence Lifecare Pvt Ltd and site to a new WHO GMP certified facility which is located at plot no. 6104/6 GIDC industrial estate, Ankleshwar- 393002 Gujrat, India and will start supplying from new facility with new name from June, 2026 onwards. New site will be inducted in Pharmevo as per new details given. | N/A | Approved | 31/01/2029 | In Progress | Pharma | 01) Variation will be submitted in local and export countries after completion of PV and Stability. (RA)
02) Source approval documents from the new site will be submitted to QA. (SCM)
03) Vendor list will be updated by adding new vendor name and site and excluding previous vendor name and site. (QA)
04) New manufacturer name and site will be added in SAP and previous name and site will be deleted. (SCM)
05) Procurement of raw material from new site of the manufacturer. (SCM)
06) Process validation will be perform on three consecutive batches. QA (Val)
07) Stability will be perform on validation batches. (QC)
|
| 01) Jan-29
02) March-27
03) April-27
04) March-27
05) March-28
06) Dec-28
07) Dec-28
| Muhammad Haris | 30/01/2026 | Muhammad Haris | 03/08/2026 |
|
| CMP-0021-26 | 30/01/2026 | RA | Permanent | Minor | Change in batch size of SPS 100g Jar. | Currently batch size of SPS 100g SFG Jar is 35Kg. It is ready to fill product. | It is proposed to change this to flexible batch size to meet market demand. | N/A | Approved | 28/02/2026 | Closed | Pharma | 01) BDR will be revise. (QA)
| 01) Done
| 01) Feb-26
| Muhammad Haris | 30/01/2026 | Muhammad Haris | 18/03/2026 |
|
| CMP-0022-26 | 02/02/2026 | Production | Permanent | Moderate | Change of Pack size for local manufacturing of Xcept 15mg and 20mg tablet. | At present, the below mentioned products are blister on the BM-350 using 10's blister tooling. During operation, three blister pockets are intentionally left empty (Pic attached). The final pack configuration is 14's (2 x 7 tablets).
1. Xcept 15mg tab.
2. Xcept 20mg tab. | It is now proposed to utilize all blister pockets during blister operations on the BM-350. The existing blister tooling will be used without leaving any empty pocket. New pack size will be decided in change impact assessment. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Artwork will be develop as per 10’s pack size. (BD)
02) Item codes will be open. (BD)
03) Existing inventory will be consume. (SCM)
04) FG code will be open. (SCM)
05) Procurement of packaging material as per new approved artwork of pack size 10’s. (SCM)
06) BOM will be revise in SAP. (SCM)
07) BPR will be revise. (SCM)
08) Specifications will be update in SAP. (QC)
|
| 01) June-26
02) June-26
03) June-26
04) June-26
05) July-26
06) Aug-26
07) Aug-26
08) Aug-26
| Muhammad Haris | 02/02/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0023-26 | 02/02/2026 | Warehouse | Permanent | Minor | To change the format of GI, LC and MO in BDR and BPR. | In BDR,
1. In LC differential pressure of dispensing areas and laminar air pressure not mentioned.
2. In LC Expiry date of API is mentioned.
3. In MO, QC lot, Net qty issued, tare weight, gross weight , dispensed by, checked by, potency and adjustment are mention manually at the time of dispensing.
In SAP generated GI.
In GI columns with heading (To) (Balance) and (Status) are mentioned. | In BDR,
1. In LC differential pressure of dispensing areas and laminar air pressure will be added.
2. In LC Expiry date of API will be removed , as it is mentioned in GI.
3. In MO, QC lot, net qty issued, tare weight, gross weight, dispensed by, checked by, potency and adjustment will be removed because it is already part of GI.
In SAP generated GI
In GI columns with heading (To) (Balance) and (status) will be removed and further two columns with heading (dispensed by) (checked by) will be added GI.
| N/A | Approved | 31/12/2026 | In Progress | Pharma | 01) Changes will be made in SAP output form. (MIS)
02) UAT will be prepared. QA(Val)
03) PQ will be perform. QA(Val)
04) BDR will be revise. (QA)
|
| 01) June-26
02) June-26
03) July-26
04) Dec-26
| Muhammad Haris | 02/02/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0024-26 | 02/02/2026 | RA | Permanent | Minor | Spelling correction in the artwork of Aireez 4mg Sachet- Vietnam | A few spelling mistakes were identified in the DI of Aireez Sachet 4mg (Vietnamese Language). | The partner has requested correction of the spelling mistakes in the DI. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Artwork will be revise. (BD)
02) New item code will be open. (BD)
03) Existing inventory will be write off. (SCM)
04) BOM will be revise in SAP. (QA)
05) Procurement of DI as per revised artwork. (SCM)
| 01) Done
02) Done
03) Done
04) Done
05) Done
| 01) Done
02) Done
03) Done
04) April-26
05) March-26
| Muhammad Haris | 02/02/2026 | Muhammad Haris | 22/06/2026 |
|
| CMP-0025-26 | 02/02/2026 | BD | Permanent | Major | Launch of New Product in Ghana. | The product mentioned below are not launched in Ghana yet.
Product: Galvecta Plus 50/500mg. Generic: Vildagliptin+ Metformin. Pack Size: 56's. Shelf Life: 24months. Registration Timeline: Registered.
Product: Galvecta Plus 50/1000mg. Generic: Vildagliptin+ Metformin. Pack Size: 56's. Shelf Life: 24months. Registration Timeline: Registered. | These products are planned for launch in Ghana. | RA-0045-25 | Approved | 31/08/2026 | Closed | Pharma | 01) Registration letter required. (RA)
02) Product launch in Ghana. (BD)
03) Development and approval of artwork. (BD)
04) New item code will be open. (BD)
05) FG code will be open. (SCM)
06) BOM will be create in SAP. (QA)
07) BPR will be prepared. (QA)
08) Procurement of packaging material. (SCM)
09) Specification will be developed in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
06) Done
06) Done
07) Done
08) Done
09) Done
| 01) Done
02) Aug-26
03) Done
04) Done
05) Done
06) Aug-26
07) Aug-26
08) March-26
09) Aug-26
| Muhammad Haris | 02/02/2026 | Muhammad Haris | 12/09/2026 |
|
| CMP-0026-26 | 03/02/2026 | SCM | Permanent | Major | Alternate Vendor Qualification for Omeprazole Pellets from Vision Pharmaceutical (Pvt) Ltd. Site Address: Plot No: 22-23, Industrial Triangle Kahuta Road, Islamabad, Pakistan | Omeprazole pellets are currently procured from M/S Cohance Life Sciences and comply with the USP dissolution Test I. However, due to relocation and ongoing development of the supplier’s manufacturing facility, procurement from Cohance Life Sciences is currently not feasible.
Site Address: Plot No. A-19C, A-23A & A-23B, Road. No. 18, I.D.A., Nacharam, Medchal-Malkajgiri District- 500076, Telangana, India.
| It is proposed to procure omeprazole pellets from and alternate vendor i.e. Vision Pharmaceutical (Pvt) Ltd. to ensure continuity of supply. The proposed supplier claims compliance with USP specifications, with disolution meeting the USP requirement at Test II. | RA-0008-26-P | Approved | 30/11/2026 | In Progress | Pharma | 01) PD trial documents required. (PD)
02) Source approval document will be submitted to QA. (SCM)
03) Procurement of material from new source. (SCM)
04) Vendor list will be updated by adding new vendor name and site and excluding previous vendor name and site. (QA)
05) Artwork will be revise. (BD)
06) Item code will be open. (BD)
07) Process validation will be perform. QA(Val)
08) Stability will be perform on validation batches. (QC)
09) AMV will be perform. (PD)
10) Testing method will be revise. (QC)
11) Specification will be revise. (QC)
12) Source name will be added in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
09) Done
10) Done
11) Done
12) Done
| 01) Done
02) Done
03) April-26
04) March-26 (Extension till Aug-26)
05) March-26
06) March-26
07) Nov-26
08) Nov-26
09) April-26 (Extension till July-26)
10) April-26
11) April-26
12) Done
| Muhammad Haris | 03/02/2026 | Muhammad Haris | 12/09/2026 |
|
| CMP-0027-26 | 04/02/2026 | BD | Permanent | Moderate | To shift launched products in FWA region from country specific to Group (Shelf life specific) | Currently, products launched in FWA are categorized based on specific countries. | Products will be categorized into two groups based on shelf life instead of region/ countries:
1. FWA-A: 24 months
2. FWA-B: 36 months
Finished products codes will be created according to these groups.
Packaging material codes (A/F, U/C, D/I) will remain unchanged. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) FG code will be open. (SCM)
02) SCM will intimate QA for the updation of BOM. (SCM)
03) BOM will be revise in SAP. (QA)
| 01) Done
02) Done
03) Done
| 01) Done
02) March-26
03) April-26
| Muhammad Haris | 04/02/2026 | Muhammad Haris | 07/05/2026 |
|
| CMP-0028-26 | 09/02/2026 | Warehouse | Permanent | Moderate | Change in the dispensing process of EHGC shell. | Currently, we dispensed EHGC shell in Kg but in MO EHGC shell mention in NOS and we also receive EHGC in NOs. As we know that EHGC are moisture sensitive, multiple time cartons are open for dispensing of EHGC shell and there is chance of shell damages due to edges of scoop. | We will dispense the MO quantity of EHGC shells in NOs as mentioned by vendor on the container. Only loose quantity will be dispensed in Kg. | N/A | Approved | 30/06/2026 | In Progress | Pharma | 01) UOM need to be change in SAP. (WH)
|
| 01) June-26
| Muhammad Haris | 09/02/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0029-26 | 12/02/2026 | QA | Permanent | Major | Change in finished product specification of Perabactum Injection range (1g IV/IM, 2g IV/IM) | Currently, Perabactum Injection Range specification is aligned as per Japanese Pharmacopoeia (JP). | It is proposed to revise finished product specifications of Perabactum Injection range from Japanese Pharmacopoeia (JP) specification to the Innovator's specifications. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Item code will be open. (BD)
02) Old inventory will be destructed. (SCM)
03) Procurement of packaging material. (SCM)
04) BOM will be revise in SAP. (QA)
05) Testing method of RM and FG will be revise. (QC)
06) Stability specification will be updated. (QC)
07) Specification will be update in LIMS. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
07) Done
| 01) Done
02) April-26
03) March-26
04) April-26
05) March-26
06) March-26
07) March-26
| Hamza Ahmed | 12/02/2026 | Muhammad Haris | 09/05/2026 |
|
| CMP-0030-26 | 12/02/2026 | QC | Permanent | Minor | Transfer of Stability Chamber responsibility from Quality Control to Product Development. | As per the current procedure, the Quality Control (QC) department is responsible for the maintenance and calibration of stability chamber 01, 02, 08, 10, 12 and 16, which are used by the Product Development (PD) department. | It is proposed that the responsibility for maintenance and calibration of stability chambers 01, 02, 08, 10, 12 and 16 is transferred to the Product Development (PD) department. | N/A | Approved | 31/05/2026 | Closed | Pharma | 01) QC will transfer the responsibility of the stability chamber to PD. (QC)
02) QC will submit Chamber maintenance record and IQ, OQ documents to PD. (QC)
03) SOP of chamber will be prepared. (PD)
04) Log book will be prepred for placing samples in the stability chamber. (PD)
05) QC will update the instrument list by excluding the stability chambers 01, 02, 08, 10 and 12. (QC)
06) PD will update the instrument list by including the stability chambers 01, 02, 08, 10 and 12. (PD)
07) Calibration list will be update. QA (Val)
08) A new equipment ID for the stability chamber will be assigned for the Product Development Department. (Engineering)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
07) Done
08) Done
| 01) March-26
02) March-26
03) May-26 (Extension till Aug-26)
04) May-26 (Extension till Aug-26)
05) April-26 (Extension till Aug-26)
06) May-26 (Extension till Aug-26)
07) May-26 (Extension till Aug-26)
08) May-26 (Extension till Aug-26)
| Muhammad Haris | 12/02/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0031-26 | 13/02/2026 | Warehouse | Permanent | Major | Development and implantation of Extended Warehouse Management. | Currently we are using SAP for inventory management and traceability through different reports. There is no proper visibility and traceability of stock in the warehouse. | We will develop and implement extended warehouse management (EWM) to enhance stock visibility and traceability in the warehouse. Furthermore it helps in optimization of process time and space utilization. | RA-0009-26-P | Approved | 30/06/2026 | Closed | Pharma | 01) URS to be developed. (WH)
02) Development of EWMS in SAP. (WH)
03) Testing will perform in testing server. (WH)
04) IQ, OQ and PQ will perform. QA(Val)
| 01) Done
02) Done
03) Done
04) Done
| 01) April-26
02) June-26
03) June-26
04) June-26
| Hamza Ahmed | 13/02/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0032-26 | 18/02/2026 | RA | Permanent | Major | Overprinting of QR matrix code on unit carton of Pharmaceutical and Nutraceutical products exporting to Tajikistan | Currently products exporting in Tajikistan only contain batch number, manufacturing date and expiry date on finished product. | It is proposed to carry out overprinting of QR matrix codes on the unit cartons of Pharmaceutical and Nutraceutical products intended for export to Tajikistan as per the following information. The QR matrix code will contain specific product information. This data will be provided by our partner inTajikistan in the form of an excel sheet. The data in the sheet will be converted in the form of data matrix code. The information will be unique to each individual unit carton and will be shared by the partner separately for each upcoming order destined for the Tajikistan market.
While following information will be printed in human readable form in the following format:
Batch No:
MFG:
EXP: | N/A | Approved | 31/12/2026 | In Progress | Pharma | 01) Specific product information in the form of excel sheet for the printing of QR matrix code will be provided. (RA)
02) Excel sheet data will be integrated with the pharmaTrax software for code management. (RA)
03) Tertiary packaging (Master carton) label will be generated through pharmTrax software containing all information of unit carton. (RA & Production)
04) Instruction will be incorporated in EPO. (SCM)
05) For every upcoming order for Tajikistan, (SCM) will inform immediately to RA for the issuance of verification code/Information. (SCM & RA)
06) SOP to be developed for the QR code management for Tajikistan. (RA)
|
| 01) Dec-26
02) Dec-26
03) Dec-26
04) Dec-26
05) Dec-26
06) Dec-26
| Muhammad Haris | 18/02/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0033-26 | 20/02/2026 | SCM | Permanent | Moderate | Institution order of SHM Lowplat Plus. | Order of DGH Specialized order is received from institution market. | We have reviewed order of following products from PIC Bahawalpur Order:
Products: Lowplat Plus 75mg 1x10's. QTY: 1,000,000. Printing Requirements: BOMs will be opened with Pre-printed foil will be used with green commercial pack codes.
Order need to be provided with above mentioned artwork and pack size.
For Aluminium Foil:
Base color in green with Punjab Govt. Logo, "Punjab Govt Property" "Not for Sale" both in english and urdu. "SHC & MED"
For Green Box:
Green Box, product logo and detail, Traceable GTIN, Punjab Govt. Logo, "Punjab Govt Property" "Not for Sale" both in english and urdu, "Specialized Health Care & Medical Education Department Punjab" | N/A | Approved | 31/05/2026 | Closed | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) BOM will be created in SAP. (QA)
05) BPR will be prepared. (QA)
06) Specification will be updted in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) March-26
02) March-26
03) March-26
04) May-26
05) May-26
06) May-26
| Muhammad Haris | 20/02/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0034-26 | 20/02/2026 | Production | Permanent | Minor | It is proposed to shift SPS Jar Ranges from manual labelling to auto labelling machine. | Currently, labelling process for SPS Jar Range is manual in general pharma. | It is proposed to shift SPS Jar Range from manual labelling to auto bottle labelling machine installed in packaging area for General Pharma. | N/A | Approved | 31/12/2026 | Opened | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) Old inventory will be consume. (SCM)
04) Procurement of new labels. (SCM)
05) BOM will be revise in SAP. (QA)
06) Specification will be update in SAP. (QC)
07) Qualification will be performed. QA(Val)
| 01) Done
02) Done
| 01) April-26 (Extension till Sep-26)
02) April-26 (Extension till Sep-26)
03) Oct-26
04) Aug-26 (Extension till Oct-26)
05) Aug-26 (Extension till Nov-26)
06) Aug-26 (Extension till Nov-26)
07) Dec-26
| Muhammad Haris | 20/02/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0035-26 | 25/02/2026 | Production | Permanent | Major | Addition of 3 new tablet de-duster (Model: SZS-750) | Currently, we have procured 3 new tablet de-dusters (Model: SZS-750) for compression use in production non-cephalosporin building. | It is proposed to add 3 newly procured tablet de-duster (Model: SZS-750) for compression machine (ZPW-23, ZPW-26 A & B) in compression section of production non-cephalosporin building. | RA-0011-26-P | Approved | 30/09/2026 | Opened | Pharma | 01) DQ, IQ, OQ and PQ of equipment will be perform. QA(Val)
02) SOP will be revise. (Prod)
03) Training will be provided to concern person. (Prod)
04) Preventive maintenance plan will be update. (Eng)
05) Equipment list will be revise. (Eng)
| 01) Done
| 01) May-26
02) April-26 (Extension till Sep-26)
03) April-26 (Extension till Sep-26)
04) Sep-26
05) Sep-26
| Muhammad Haris | 25/02/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0036-26 | 25/02/2026 | Production | Permanent | Major | Change in thickness limit. | Currently, the thickness limit of Avsar Plus 160/10/25mg tablet is 4.80mm (4.50-5.10)mm as per BMR specification. | It is proposed to revise the thickness limit of Avsar Plus 160/10/25mg tablet 4.70mm (4.30-5.10)mm to 5.30mm (4.90-5.70)mm as per improved hardness. | RA-0010-26-P | Approved | 30/09/2026 | Opened | Pharma | 01) BMR will be revise. (QA)
02) Testing method will be revise. (QC)
03) Process validation will be perform on three batches. QA(Val)
04) Stability will be perform on validation batches. (QC)
05) Specification will be update in SAP. (QC)
| 01) Done
02) Done
05) Done
| 01) April-26
02) April-26
03) Sep-26
04) Sep-26
05) April-26
| Muhammad Haris | 25/02/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0037-26 | 26/02/2026 | Production | Permanent | Major | Transferring of products to Hoonga Blister Machine Local CP. | The products mentioned on the attached list are currently blistered on BM 350 blister machine as per mentioned dimensions (list attached). A/F 266mm & CFF 268mm. List attached. | The products mentioned on the attached list are agreed to move to the Hoonga Blister Machine as per mentioned dimensions (list attached). A/F 288mm & CFF 290mm | N/A | Approved | 30/06/2027 | Opened | Pharma | 01) Intimation to be submitted in DRAP. (RA)
02) Development and approval of artwork. (BD)
03) New item codes will be open. (BD)
04) Existing inventory will be consume. (SCM)
05) Procurement of packaging material. (SCM)
06) New tooling will be required. (Production)
07) BOM will be revise in SAP. (QA)
08) BPR will be revise. (QA)
09) Process validation will be performed on blistering stage. QA (Val)
10) Specifications will be update on SAP. (QC)
|
| 01) Nov-26
02) Oct-26
03) Oct-26
04) Nov-26
05) Nov-26
06) Sep-26
07) Dec-26
08) Dec-26
09) June-27
10) Dec-26
| Muhammad Haris | 26/02/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0038-26 | 27/02/2026 | RA | Permanent | Minor | Change of Finished Product Specification for Pregab-Q (Pregablin) 25mg & 75mg Capsules from In-House to BP. | The existing specifications for Pregab-Q (Q-Pharma, Kenya) is in-house. | New Specifications approved for Pregab-Q (Q-Pharma, Kenya) is BP. | N/A | Approved | 31/05/2026 | In Progress | Pharma | 01) Development and approval of artwork (A/F, U/C and DI). (BD)
02) Item code will be open. (BD)
03) BOM will be update in SAP. (QA)
04) Specification will be update in SAP. (QC)
|
| 01) May-26 (Extension till Aug-26)
02) May-26 (Extension till Aug-26)
03) May-26 (Extension till Aug-26)
04) May-26 (Extension till Aug-26)
| Muhammad Haris | 27/02/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0039-26 | 27/02/2026 | SCM | Permanent | Minor | Addition of Supplier for Local Materials. | Currently, we are procuring Iso Propyl Alcohol (IPA) from supplier as per attached sheet. | It is proposed to add one more supplier "Mars Chemicals (Private) Limited" Address: 805, Anum Estate, Shahrah-e-Faisal, Karachi.
For the procurement of above mentioned materials from the same approved manufacturer's as mentioned in attached list. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Approved vendor list will be update. (QA)
02) Supplier name will be added in SAP. (SCM)
| 01) Done
02) Done
| 01) April-26
02) April-26
| Muhammad Haris | 27/02/2026 | Muhammad Haris | 07/05/2026 |
|
| CMP-0040-26 | 27/02/2026 | SCM | Permanent | Minor | Addition of Supplier for Local Materials. | Currently, we are procuring Iso Propyl Alcohol (IPA) USP, Methylene Chloride from supplier as per attached sheet. | It is proposed to add one more supplier "Cheminova Corporation" Address: Plot No. 10, Block 7/8 KMCHS, near Hill Park, Karachi.
For the procurement of above mention material from the Approved Manufacturer, LCY Taiwan, Inovyn Chlor Ltd, Ineos Chlor Ltd, Integrated Commercial Ventures (ICV) China.
| N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Approved vendor list will be update. (QA)
02) Supplier name will be added in SAP. (SCM)
| 01) Done
02) Done
| 01) April-26
02) April-26
| Muhammad Haris | 27/02/2026 | Muhammad Haris | 09/05/2026 |
|
| CMP-0041-26 | 04/03/2026 | PD | Permanent | Major | New launch product Bethanechol Chloride 10mg and 25mg tablet. | Product development activities of generic Bethanechol Chloride 10mg and 25mg tablet has been completed. | It is proposed to commercialize Bethanechol Chloride 10mg and 25mg tablet in pharmevo facility.
Batch size for Bethanechol Chloride 10mg is 100,000 tablet (20kg)
Batch size for Bethanechol Chloride 25mg is 50,000 tablet (25kg) | RA-0012-26-P | Approved | 31/03/2027 | Opened | Pharma | 01) Trail documents required. (PD)
02) Stability study documents required (three months accelerated and long term stability). (PD)
03) Containment approach report is required. (PD)
04) Cleanibility report is required. (PD)
05) Technology transfer protocol (for process) is required. (PD)
06) Technology transfer protocol (for analytical testing) is required. (PD)
07) Source approval documents will be sumitted to QA. (SCM)
08) Procurement of raw material. (SCM)
09) Artwork will be develop and approved. (BD)
10) Item code will be open for new develop artwork. (BD)
11) Procurement of packaging material. (SCM)
12) Analytical testing method will be prepare. (QC)
13) BOM will be create in SAP. (QA)
14) Batch documents (BDR, BMR and BPR) will be prepared. (QA)
15) Routing will be create in SAP. (Production)
16) Planning of product launch for commercial. (BD)
17) Process Validation will be perform. QA (Val)
18) Hold Time Study will be perform. QA (Val)
19) Assessment will be perform for cleaning validation. QA (Val)
20) Product will be charge on stability study. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
13) Done
14) Done
15) Done
| 01) Done
02) Done
03) June-26
04) June-26
05) June-26
06) June-26
07) July-26 (Extension till Oct-26)
08) Aug-26 (Extension till Jan-27)
09) June-26 (Extension till Dec-26)
10) June-26 (Extension till Dec-26)
11) Aug-26 (Extension till Jan-27)
12) Aug-26 (Extension till Oct-26)
13) Aug-26
14) Aug-26
15) Aug-26
16) Aug-26
17) Dec-26 (Extension till)
18) March-27 (Extension till)
19) Dec-26 (Extension till)
20) Dec-26 (Extension till)
| Hamza Ahmed | 04/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0042-26 | 06/03/2026 | QC | Permanent | Major | Addition of new Thin Layer Chromatography appratus in QC laboratory (Non Ceph Area) | Currently QC lab do not have TLC appratus for identification test. | It is proposed to procure an apparatus for Thin Layer Chromatography in the Quality control Laboratory.
S.No: 01. Equipment Name: Thin Layer Chromatography Apparatus. Vendor: IMCO. Make: Local. Quantity: 01. | RA-0013-26-P | Approved | 30/04/2026 | Closed | Pharma | 01) SOP for Thin Layer Chromatography Plate will be develop. (QC)
02) Training will be provided to concern staff. (QC)
| 01) Done
02) Done
| 01) April-26
02) April-26
| Muhammad Haris | 06/03/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0043-26 | 13/03/2026 | BD | Permanent | Major | Launch of Glyzempa 10mg and Glyzempa 25mg for Exphar in French West Africa. | The products mentioned below are not launched yet.
S.No. 01. Products: Glyzempa 10mg. Generic: Empagliflozin. Pack Size: 4x7's. Shelf Life: 24months. Registration Timeline: Registered.
S.No. 02. Products: Glyzempa 25mg. Generic: Empagliflozin. Pack Size: 4x7's. Shelf Life: 24months. Registration Timeline: Registered. | These products will be manufactured for Exphar and Exphar will market these products in French West Africa. These products will solely be manufactured for Exphar. | N/A | Approved | 31/07/2026 | Closed | Pharma | 01) Development and approval of artwork. (BD)
02) New item codes of packaging material will be open. (BD)
03) Specification of packaging material will be developed in SAP. (QC)
04) Procurement of packaging material. (SCM)
05) New item code of API will be open by mentioning the manufacturer name with API name. (SCM)
06) Procurement of API from approved source by Exphar. (SCM)
07) SFG and FG codes will be open. (SCM)
08) SFG and FG BOM will be create in SAP. (QA)
09) Batch documents (BDR, BMR, BYS and BPR) will be prepared. (QA)
10) Routing will be create in SAP. (Production)
11) SOP for Management of Exphar Products will be prepared. (QA)
12) Product launch in Exphar. (BD)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
07) Done
08) Done
09) Done
10) Done
11) Done
12) Done
| 01) April-26
02) April-26
03) May-26
04) May-26
05) April-26
06) April-26
07) April-26
08) May-26
09) May-26
10) May-26
11) June-26
12) July-26
05)
06)
07)
08) May-26
09) May-26
10) May-26
11) June-26
12) July-26
| Muhammad Haris | 12/03/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0044-26 | 12/03/2026 | PD | Permanent | Major | Manufacturing of batches for submission of WHO dossier of Spectrix 250mg and 500mg tablets with improved formulation. | Product development activities of Spectrix 250mg and 500mg tablets with improved formulation has been completed. | It is proposed to manufacture three batches of Spectrix 250mg and 500mg from API manufacturer "Shangyu Jingxin Pharmaceutical CP Ltd" in Pharmevo facility. Proposed batch size will be as follows:
1) Spectrix 250mg tablet: 150,515 tablets
2) Spectrix 500mg tablets: 50,000 tablets | RA-0016-26-P | Approved | 31/05/2027 | In Progress | Pharma | Spectrix 250mg Tablets:
01) Lab scale trial will be performed. (PD)
02) Trial batch will be charge on stability. (PD)
03) Regulatory will submit the variation in DRAP for change in formulation (Batch will be manufacture after approval) (RA)
04) Technology transfer protocol (for process) will be developed. (PD)
05) Technology transfer protocol (for analytical testing) will be developed. (PD)
06) Placebo sample will be submitted to QC for AMV. (PD)
07) AMV will be performed for both raw material and finished product. (QC)
08) Batches of Spectrix 250mg tablet will be manufacture with old formulation to cover six month market requirement. (SCM)
09) New API code will be open with the name Levofloxacin Hemihydrate (WHO Grade). (SCM)
10) Quantity of Levofloxacin (150.00Kg) will be transferred to new opened code of API from PD code. (WH)
11) Manual inspection lot will be created. (QC)
12) Raw material impurity will be procured. (QC)
13) Impurity testing will be performed for both raw material and finished product. (QC)
14) Testing of Levofloxacin from manufacturer "Shangyu Jingxin Pharmaceutical CP Ltd" will be perform. (QC)
15) Compression tooling will be procured for Spectrix 250mg tablet. (Production)
16) Review of artwork as per the WHO requirement. (BD & RA)
17) Revision of artwork if required. (BD & RA)
18) SFG BOM will be revised as per new formulation. (QA)
19) Availability of all required raw and packaging materials as per BOM for three batches. (SCM)
20) Batch documents will be prepared. (QA)
21) Blister operation will be performed on BM-350B machine and only BM-350B machine is the part of BPR. (Production)
22) Routing will be create in SAP. (Production)
23) Planning of spectrix 250mg tablet batches. (SCM)
24) Manufacturing of Spectrix 250mg tablet batches. (Production)
25) NDMA/ NDEA samples will be collected and submitted to QC. (QA)
26) QC will send these samples for outsource testing. (QC)
27) Process validation will be performed. QA (Val)
28) Hold time study will be performed. QA (Val)
29) Cleaning validation will be performed. QA (Val)
30) Product will be charge on stability. QC
31) Dossier will be prepared and submitted. (RA)
Spectrix 500mg Tablets:
01) LAb scale trial will be performed. (PD)
02) Trial batch will be charge on stability. (PD)
03) Regulatory will submit the variation in DRAP for change in formulation (Batch will be manufacture after approval). (RA)
04) Technology transfer protocol (for process) will be developed. (PD)
05) Technology transfer protocol (for analytical testing) will be developed. (PD)
06) Placebo sample will be submitted to QC for AMV. (PD)
07) AMV will be performed for both raw material and finished product. (QC)
08) Batches of Spectrix 500mg tablet will be manufacture with old formulation to cover six month market requirement. (SCM)
09) New API code will be open with name Levofloxacin Hemihydrate (WHO Grade)
10) Quantity of Levofloxacin (150.00Kg) will be transferred to new opened code of API from PD code. (WH)
11) Manual inspection lot will be created. (QC)
12) Raw material impurity will be procured. (QC)
13) Impurity testing will be performed for both raw and finshed product.(QC)
14) Testing of Levofloxacin from manufacturer “Shangyu Jingxin Pharmaceutical CP Ltd” will be perform. (QC)
15) Review of artwork as per the WHO requirement. (BD& RA)
16) Revision of artwork if required. (BD & RA)
17) SFG BOM will be revised as per new formulation. (QA)
18) Availability of all required raw and packaging materials as per BOM for three stability batches. SCM
19) Batch documents will be prepared. QA
20) Blister operation will be performed on BM-350B machine and only BM-350B machine is the part of BPR. (Production)
21) Routing will be create in SAP. (Production)
22) Planning of Spectrix 500mg tablet batches. SCM
23) Manufacturing of spectrix 500mg tablet batches. Production
24) NDMA/NDEA samples will be collected and submitted to QC. QA
25) QC will send these samples for outsource testing. QC
26) Process validation will be performed. QA(Val)
27) Hold time study will be performed. QA(Val)
28) Cleaning validation will be performed. QA(Val)
29) Product will be charge on stability. QC
30) Dossier will be prepared and submitted. RA
|
| Spectrix 250mg Tablet:
01) Aug-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Aug-26
06) Aug-26
07) Aug-26
08) Aug-26
09) Aug-26
10) Aug-26
11) Aug-26
12) Aug-26
13) Sep-26
14) Oct-26
15) Oct-26
16) Oct-26
17) Oct-26
18) Nov-26
19) Nov-26
20) Nov-26
21) Nov-26
22) Nov-26
23) Dec-26
24) Dec-26
25) Dec-26
26) Dec-26
27) March-27
28) May-27
29) March-27
30) March-27
31) April-27
Spectrix 500mg Tablet:
01) Aug-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Aug-26
06) Aug-26
07) Aug-26
08) Aug-26
09) Aug-26
10) Aug-26
11) Aug-26
12) Aug-26
13) Sep-26
14) Sep-26
15) Sep-26
16) Sep-26
17) Oct-26
18) Oct-26
19) Oct-26
20) Oct-26
21) Oct-26
22) Nov-26
23) Nov-26
24) Nov-26
25) Nov-26
26) March-27
27) May-27
28) March-27
29) March-27
30) April-27
| Muhammad Haris | 12/03/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0045-26 | 24/03/2026 | SCM | Temporary | | Redressing of Finished Products Intended for Afghanistan Market to Local CP. | Finished products were manufactured and labeled for export to Afghanistan due to suspension of trade relations and export restriction, distribution is no longer permitted, rendering the stock unusable in its current form. Additionally, certain batches were parttially released earlier in local CP, necessitating clear identification and traceability of remaining quantities.
| To redress the existing stock through controlled relabelling and/ or repackaging in compliance with local regulatory requirements (refer attached list of finished products). For partially released batches, a defined suffix "R" will be appended to the batch numbewr to ensure identification, segregation, and traceability of redressed quantities. (E.g: Batch Number 5J001 will be 5J001R) and this batch number will be printed on unit carton only. | N/A | | | Closed | Pharma |
| Closed Without Implementation
|
| Muhammad Haris | 24/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0046-26 | 24/03/2026 | SCM | Permanent | Major | Additional source induction of Orlistat Pellets 50%. | We have approved sources for Orlistat Pellets 50% as M/S ALPHAMED FORMULATION PVT. LTD & Surge Labs Pvt Ltd. | We intend to induct one more source M/s. Biocon Limited. Address: Special Economic Zone Plot no. 2, 3, 4 & 5, Phase IV Bommasandra-Jigani Link Road, Bommasandra post Bengaluru-560099 Karnataka, INDIA. | N/A | Approved | 31/12/2026 | Closed | Pharma | 01) Source approval documents will be submitted to QA. (SCM)
02) Procurement of material from new source. (SCM)
03) Vendor list will be update. (QA)
04) Source name will be added in SAP. (QA)
05) Process validation will be perform. QA(Val)
06) Stability will be perform on validation batches. (QC)
| Closed Without Implementation.
| 01) April-26
02) Aug-26
03) May-26
04) May-26
05) Dec-26
06) Dec-26
| Muhammad Haris | 24/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0047-26 | 25/03/2026 | PD | Permanent | Major | Manufacturing of Zi-AD tablet 5mg for submission of dossier in WHO as per EOI | Currently, Zi-AD 20mg Dispersible tablet is prequalified in WHO with WHO reference number (D1009) | It is proposed to manufacture Zi-AD 5mg Dispersible tablet in Pharmevo as per WHO expression of interest with source of Zinc Sulphate as Canton Labourtries Pvt Ltd. The tablet weight is increase from 95mg/tablet to 120mg/tablet. The tablet is compressed at 7.00mm punch. | RA-0017-26-P | Approved | 30/11/2026 | Opened | Pharma | 01) Orange Trusil Flavor Powder Sc085569 Tab will be procured. (SCM)
02) Analytical and micro testing will be performed for Orange Trusil Flavor Powder Sc085569 Tab. (QC)
03) PD trial document is required along with the analytical report. (PD)
04) Placebo and sample will be submitted to QC for AMV. (PD)
05) Method verification to be performed. (QC)
06) Technology transfer protocol(for process) will be developed. (PD)
07) Technology transfer protocol(for analytical testing) will be developed. (PD)
08) New punches(Fette Compression machine) will be procured. (Production)
09) Blister tubes will be procured. (Production)
10) Verification of punches and tubes will be performed. (Production/PD)
11) Artwork will be revised.(U/C, D/I,A/F). (BD)
12) New item code will be opened for the revised artwork. (BD)
13) Procurement of material as per revised artwork. (SCM)
14) New item code will be open for the API, Excipients and primary packaging material by mentioning the manufacturer name. (SCM & BD)
15) BOM will be created in SAP. (QA)
16) Batch Documents will be revised. (QA)
17) Availibilty of raw and packaging material. (SCM)
18) Planning of Zi-AD batches for dispensing. (SCM)
19) Manufacturing of Zi-AD batches. (Production)
20) Submission of finished product samples to QC for NDMA/NDEA testing. (QA)
21) QC will send these sample for outsource testing of NDMA/NDEA. (QC)
22) Process validation will be performed QA(Val)
23) Product will be charge on stability. (QC)
24) Cleaning validation will be performed. QA(Val)
25) Hold time study will be performed. QA(Val)
26) Batch will be hold till six month stability results. (QA)
27) Dossier will be prepared and submitted in DRAP. (RA)
28) Dossier will be prepared and submitted in WHO. (RA)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
07) Done
08) Done
09) Done
10) Done
11) Done
12) Done
13) Done
14) Done
15) Done
16) Done
17) Done
18) Done
19) Done
20) Done
21) Done
22) Done
23) Done
24) Done
26) Done
| 01) April-26
02) April-26
03) April-26
04) April-26
05) April-26
06) May-26
07) May-26
08) June-26
09) June-26
10) June-26
11) May-26
12) May-26
13) May-26
14) May-26
15) May-26
16) May-26
17) May-26
18) July-26
19) July-26
20) July-26
21) July-26
22) July-26
23) July-26
24) July-26
25) Nov-26
26) Aug-26
27) Aug-26 (Extension till Sep-26)
28) Aug-26 (Extension till Sep-26)
| Hamza Ahmed | 25/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0048-26 | 25/03/2026 | PD | Permanent | Major | Manufacturing of Zi-AD syrup 5mg/5ml for submission of dossier in WHO as per EOI | Currently, Zinc Sulphate Oral Solution is pre qualified in WHO having WHO reference number (D1010) being manufactured with source Zinc Sulphate as DR. Paul Lohman GMBH. KG source. | It is proposed to develop Zinc Sulphate Oral Solution in Pharmevo as per WHO Expression of Intrest with source of Zinc Sulphate as Canton Labourtries Pvt. Ltd | RA-0018-26-P | Approved | 30/11/2026 | Opened | Pharma | 01) Orange Trusil Flavor Powder SN942166 Syp will be procured. (SCM)
02) Analytical and micro testing will be performed for Orange Trusil Flavor Powder Sc085569 Tab. (QC)
03) Placebo and sample will be submitted to QC for AMV. (PD)
04) Method verification to be performed. (QC)
05) Artwork will be revised(U/C, label and D/I) (BD)
06) New item code will be opened for the revised artwork. (BD)
07) Procurement of material as per revised artwork. (SCM)
08) New item code will be open for the API and Excipients by mentioning the manufacturer name. (SCM)
09) BOM will be revised in SAP. (QA)
10) Batch Documetns will be revised. (QA)
11) Availibilty of raw and packaging material. (SCM)
12) Planning of Zi-AD batches for dispensing. (SCM)
13) Manufacturing of Zi-AD batches. (Production)
14) Submission of finished product samples to QC for NDMA/NDEA and DEG/EG testing. (QA)
15) QC will send these sample for outsource testing of NDMA/NDEA and DEG/EG. (QC)
16) Process validation will be performed QA(Val)
17) Product will be charge on stability. (QC)
18) Leaching study will be performed for primary packaging material. (QC)
19) In use stability studies will be performed. (QC)
20) Hold time study will be performed. QA(Val)
21) Cleaning verification will be performed. QA(Val)
22) Batch will be hold till six month stability results. (QA)
23) Dossier will be prepared and submitted in DRAP. (RA)
24) Dossier will be prepared and submitted in WHO. (RA)
| 01) Done
02) Done
03) Done
05) Done
06) Done
07) Done
08) Done
09) Done
10) Done
11) Done
12) Done
13) Done
14) Done
15) Done
16) Done
17) Done
18) Done
19) Done
21) Done
22) Done
| 01) April-26
02) April-26
03) April-26
04) May-26
05) May-26
06) May-26
07) May-26
08) May-26
09) May-26
10) May-26
11) May-26
12) June-26
13) July-26
14) July-26
15) July-26
16) July-26
17) July-26
18) July-26
19) July-26
20) July-26
21) July-26
22) July-26
23) Aug-26 (Extension till Sep-26)
24) Aug-26 (Extension till Sep-26)
| Hamza Ahmed | 25/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0049-26 | 27/03/2026 | SCM | Permanent | Moderate | Institution order of CPEIC WIC Wazirabad Institute. | Order of CPEIC WIC Wazirabad Institute is received from institution market. | We have recieved order of following products from CPEIC WIC Wazirabad Institute Faisalabad:
Products: Evopride Tab. 4mg Inst. DGH 3x10's. Qty: 6,668. Printing Requirements: Green Unit Carton will be arranged and in-house printing will be done as per requirement of institution.
Order need to be provided with below mentioned artwork and pack size.
For Aluminium Foil:
Base color in green (Not mandatory) with Punjab Govt. logo, " CPEIC Wazirabad" (Not mandatory), "Punjab Govt Property" "Not for Sale".
For Green Box:
Green Box, product logo and details, Traceable GTIN, Punjab Govt. Logo, "CPEIC Wazirabad" "Punjab Govt Property" "Not for Sale" both in english and urdu. | N/A | Approved | 30/04/2026 | Closed | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) BOM will be create in SAP. (QA)
05) BPR will be prepare. (QA)
06) Specifications will be update in SAP. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
06) Done
| 01) Done
02) Done
03) April-26
04) April-26
05) April-26
06) April-26
| Muhammad Haris | 27/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0050-26 | 30/03/2026 | BD | Permanent | Major | Launch of New Products in Sri Lanka | The products mentioned below are not launched in Sri Lanka yet.
S.No: 01. Products: Arbi-H Tab. 300+12.5mg. Generic: Irbesartan+ HCTZ. Pack Size. 1x10's. Shelf Life: 24 months. Registration Timeline: May-26.
S.No: 02. Products: Arbi-H Tab. 300+25mg. Generic: Irbesartan+ HCTZ. Pack Size. 2x7's. Shelf Life: 24 months. Registration Timeline: May-26.
S.No: 03. Products: Arbi-H Tab. 150+12.5mg. Generic: Irbesartan+ HCTZ. Pack Size. 1x10's. Shelf Life: 24 months. Registration Timeline: May-26. | These products are planned for launch in Sri Lanka | RA-0045-25 | Approved | 30/11/2026 | Opened | Pharma | 01) Registration is required. (RA)
02) Product launch in Srilanka. (BD)
03) Development and approval of artwork. (BD)
04) Item code of packaging material will be open. (BD)
05) FG code will be open. (SCM)
06) BOM will be create in SAP. (QA)
07) BPR will be prepare. (QA)
08) Procurement of packaging material. (SCM)
09) Specification will be develop in SAP. (QC)
| 03) Done
04) Done
| 01) June-26 (Extension till Nov-26)
02) Nov-26 (Extension till Jan-27)
03) Done
04) Done
05) May-26
06) Aug-26 (Extension till Jan-27)
07) Aug-26 (Extension till Jan-27)
08) Based on sales order.
09) Aug-26 (Extension till Jan-27)
| Muhammad Haris | 30/03/2026 | Muhammad Haris | 14/09/2026 |
|
| CMP-0051-26 | 30/03/2026 | BD | Permanent | Major | Launch of New Products in French West Africa. | The products mentioned below are not launched in French West Africa (FWA-A) yet.
S.No. 01. Products: Galvecta Plus Tab. 50+1000mg. Generic: Vildagliptin+ Metformin. Pack Size: 4x7's. Shelf Life: 24 months. Registration Timeline: Registered.
S.No. 02. Products: Galvecta Plus Tab. 50+850mg. Generic: Vildagliptin+ Metformin. Pack Size: 4x7's. Shelf Life: 24 months. Registration Timeline: Registered.
S.No. 03. Products: Galvecta Tab. 50mg. Generic: Vildagliptin+ Metformin. Pack Size: 3x10's. Shelf Life: 24 months. Registration Timeline: Registered. | These products are planned for launch in French West Africa | RA-0045-25 | Approved | 31/08/2026 | In Progress | Pharma | 01) Product launch in French West Africa. (BD)
02) Development and approval of artwork. (BD)
03) Item code of packaging material will be open. (BD)
04) FG code will be open. (SCM)
05) BOM will be create in SAP. (QA)
06) BPR will be prepare. (QA)
07) Procurement of packaging material. (SCM)
08) Specification will be develop in SAP. (QC)
|
| 01) Aug-26
02) Done
03) Done
04) May-26
05) Aug-26
06) Aug-26
07) Based on sales order
08) Aug-26
| Muhammad Haris | 30/03/2026 | Muhammad Haris | 11/05/2026 |
|
| CMP-0052-26 | 30/03/2026 | BD | Permanent | Moderate | Launch of Histalis (Ebastine) 60ml Solution in Local Market through Contract Manufacturing. | Histalis (Ebastine) 60ml solution is not launched in the local market yet.
| Histalis (Ebastine) 60ml Solution is planned for launch in the Local Market through Contract Manufacturing.
Brand Name: Histalis 5mg/5ml Liquid. Generic Name: Ebastine. Dosage Form: Syrup (PET Bottle). Strength: 5mg/5ml. Pack Size (CP): 60ml. Shelf Life: 24 months. Name of Contract Manufacturer: Titlis Pharma (Pvt) Ltd. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Planning of product launch through contract manufacturing. (BD)
02) Development and approval of artwork. (BD)
03) New FG code will be open. (SCM)
04) Standard testing method will be required from contract manufacturer. (QA)
05) List of contract manufacturing will be update. (QA)
|
| 01) Aug-26
02) May-26
03) May-26
04) July-26
05) July-26
| Muhammad Haris | 30/03/2026 | Muhammad Haris | 23/04/2026 |
|
| CMP-0053-26 | 30/03/2026 | QC | Permanent | Major | Revision of Testing methods specification of Finish Product from In-house to Pharmacopeia (USP) | Following products are based on in-house specification as their testing method was not available in USP, BP and JP Pharmacopeia.
01) Dapwiz Tablet 5mg.
02) Dapwiz Tablet 10mg. | The products listed above will be official in United State Pharmacopeia from 01-06-2026. | RA-0021-26-P | Approved | 30/09/2026 | In Progress | Pharma | 01) Variation will be applied in DRAP. (RA)
02) Development and approval of artwork. (BD)
03) Item code will be open. (BD)
04) Old codes of packaging material will be block for procurement. (SCM)
05) Old inventory will be consume. (SCM)
06) Method verification will be perform. (QC)
07) Testing method will be develop as per USP. (QC)
08) BOM will be revise in SAP. (QA)
09) BPR will be prepared. (QA)
10) Packaging specification will be revise in SAP. (QC)
|
| 01) June-26
02) June-26
03) June-26
04) April-26
05) Aug-26
06) June-26
07) June-26
08) Sep-26
09) Sep-26
10) Sep-26
| Muhammad Haris | 30/03/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0054-26 | 01/04/2026 | RA | Permanent | Major | Change of Finished Product Specifications for X-Plended 5mg, 10mg & 20mg and Inosita 100mg from In-house to USP in Srilanka. | The existing specifications for X-Plended 5mg, 10mg & 20mg and Inosita 100mg is In-house for Srilankan market. | New specifications approved for X-Plended 5mg, 10mg & 20mg and Inosita 100mg is USP for Srilankan market. | RA-0021-26-P | Approved | 31/08/2026 | In Progress | Pharma | 01) Approval is required from NMRA. (RA)
02) Artwork will be revise. (BD)
03) Item code will be open. (BD)
04) Old codes of packaging material will be block for procurement. (SCM)
05) Old inventory will be consume. (SCM)
06) Procurement of packaging material. (SCM)
07) BOM will be revise in SAP. (QA)
08) Specification will be update in SAP. (QC)
|
| 01) Done
02) June-26
03) June-26
04) May-26
05) July-26
06) Aug-26
07) Aug-26
08) Aug-26
| Muhammad Haris | 01/04/2026 | Muhammad Haris | 12/06/2026 |
|
| CMP-0055-26 | 06/04/2026 | SCM | Permanent | Major | Additional source induction of Valsartan. | We have existing sources of Valsartan M/S ZHEJIANG TIANYU & ZHEJIANG HUAHAI PHARMACEUTICAL & ZHUHAI RUNDU PHARMA. | We intend to induct one more source M/s. Anhui Menovo Pharmaceutical Co., Ltd.
Address: No. 125 and No. 202, 242299, Zhongshan Road, Economic Development Zone, Guangde City, Xuancheng City, Anhui Province, China | N/A | Approved | 31/12/2026 | In Progress | Pharma | 01) Source approval documents will be submitted to QA. (SCM)
02) Procurement of material from new source. (SCM)
03) Vendor list will be update. (QA)
04) Source name will be added in SAP. (QA)
05) Process validation will be perform. QA(Val)
06) Stability will be perform on validation batches. (QC)
| 01) Done
03) Done
| 01) April-26
02) July-26
03) May-26
04) May-26
05) Dec-26
06) Dec-26
| Muhammad Haris | 06/04/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0056-26 | 15/04/2026 | SCM | Permanent | Major | Revision of batch manufacturing date determination criteria (Dispensing to Granulation Basis). | The manufacturing date of the batch is currently determined based on the batch dispensing date. | The manufacturing date of a batch will be determined based on the 1st manufacturing process i.e Granulation. | RA-0023-26-P | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 15/04/2026 | Muhammad Haris | 07/05/2026 |
|
| CMP-0057-26 | 15/04/2026 | QC | Permanent | Major | Addition of 15 new HPLCs in QC laboratory (General Pharma). | Currently, QC Lab- General Pharma (Non-Ceph) has 23 HPLCs of various makes for testing of raw material, finished products and stability products.
S.No: 01. Instrument Name: HPLC. Quantity: 23. Make: Shimadzu/ Thermo Scientific/ Agilent. | It is proposed that 15 new HPLCs will be installed in QC Lab- General Pharma (Non-Ceph).
S.No: 01. Instrument Name: HPLC. Quantity: 06. Make: Shimadzu. S.No: 02. Instrument Name: HPLC. Quantity: 09. Make: Thermo Scientific. | RA-0024-26-P | Approved | 30/06/2026 | In Progress | Pharma | 01) IQ, OQ and PQ of all instruments will be perform. (QC)
02) SOP of all instruments will be prepared. (QC)
03) Training will be provided to concern person. (QC)
04) Instrument list will be updated. (QC)
| 01) Done
02) Done
| 01) May-26
02) May-26
03) June-26
04) June-26
| Muhammad Haris | 15/04/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0058-26 | 04/05/2026 | QC | Permanent | Moderate | Shifting from manual inventory management of stability samples to SAP inventory module. | Currently, inventory of stability samples are allocated in the excel sheet of sample inventory of stability samples as per the SOP of stability studies QCG/5/016. | Now, it is proposed to transfer the manual inventory management system to SAP inventory management. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) URS will be prepared. (QC)
02) OQ and PQ will be perform. QC & QA (Val)
03) UAT will be perform. QC & QA (Val)
04) SOP of "Stability Studies Program" (QCG/2/016) will be revise. (QC)
05) SOP of SAP inventory module will be prepared and training will be provided to concern person.
| 01) Done
| 01) June-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Aug-26
| Muhammad Haris | 04/05/2026 | Muhammad Haris | 29/07/2026 |
|
| CMP-0059-26 | 05/05/2026 | SCM | Permanent | Moderate | Institution order of DGDP (Defence forces of Pakistan) | Order of DGDP Army is received from institution market. | We have reviewed order of following product DGDP Order:
Products: Anplag Tab. 90mg Inst. DGDP CP 20's. Qty: 22,500 Packs. Printing Requirements: BOMs will be opened with Pre-printed foil will be used with special printed commercial box. | N/A | Approved | 30/06/2026 | In Progress | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) BOM will be created in SAP. (QA)
05) BPR will be prepared. (QA)
06) Specification will be updated in SAP. (QC)
|
| 01) Done
02) Done
03) May-26
04) June-26
05) June-26
06) June-26
| Muhammad Haris | 05/05/2026 | Muhammad Haris | 12/06/2026 |
|
| CMP-0060-26 | 05/05/2026 | SCM | Permanent | | Implementation of Supplier Evaluation System in SAP. | Currently our system does not include a structured supplier evaluation mechanism, supplier performance and are assessed without standardized criteria. | Integration of a Supplier Evaluation System within SAP to ensure consistent and transparent assessment of suppliers based on material quality, on time delivery, payment term, price, technical support & emergency responsiveness. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 05/05/2026 | Muhammad Haris | 05/05/2026 |
|
| CMP-0061-26 | 05/05/2026 | Engineering | Permanent | Major | Replacement of all existing door shutters only in General Pharma (Non-Ceph) production floor. | Currently, there are doors installed at production floor of General Pharma (Non-Ceph) having fiber material inside while covered with color coating in order to ensure the GMP compliance and its smooth cleaning these doors are deteriorating day by day and require frequent maintenance work due to frequent paint peeling off and damages. | Considering the above, it is hereby proposed to replace all such door shutters of Production General Pharma (Non-Ceph) floor with Stainless Steel (SS) shutters in order to enhance cleanliness, ensure compliance with | RA-0028-26-P | Approved | 31/01/2027 | In Progress | Pharma | 01) Air flow direction should be verified as per validated pattern. (Engineering)
02) Magnehelic Stability will be verified. (Engineering)
03) Smoke study will be performed. (Engineering)
04) Environmental monitoring will be performed. QC (Micro)
|
| 01) Jan-27
02) Jan-27
03) Jan-27
04) Jan-27
| Muhammad Haris | 05/05/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0062-26 | 05/05/2026 | PD | Permanent | Moderate | Change in Dissolution specification of Xilica CR 82.5mg Tablet. | The current dissolution specification of the above-mentioned product is as follows:
Test: Dissolution (at 1 hour): Specifications: 14-24%
Test: Dissolution (at 4 hour): Specifications: 36-54%
Test: Dissolution (at 9 hour): Specifications: 58-78%
Test: Dissolution (at 24 hour): Specifications: NLT 80% | It is proposed to revise the dissolution profile/ specification of the product as follows:
Test: Dissolution (at 1 hour): Specifications: 12-32%
Test: Dissolution (at 4 hour): Specifications: 40-60%
Test: Dissolution (at 9 hour): Specifications: 60-80%
Test: Dissolution (at 24 hour): Specifications: NLT 80% | RA-0027-26-P | Approved | 31/07/2026 | In Progress | Pharma | 01) Justification will be submitted to QA. (PD)
02) Testing method will be revise. (QC)
03) Finish product specification will be revise in SAP. (QC)
04) Validation protocol will be update. QA(Val)
|
| 01) Done
02) July-26
03) July-26
04) July-26
| Muhammad Haris | 05/05/2026 | Muhammad Haris | 09/07/2026 |
|
| CMP-0063-26 | 13/05/2026 | International Business | Permanent | Moderate | Addition of "Distributed by:" before the distributor's name on all unit cartons in Cambodia. | Only distributor's name is over-printed on the unit cartons. | "Distributed by:" will be added before the name of the distributor. | N/A | Approved | 30/06/2026 | In Progress | Pharma | 01) Trial will be perform for inkjet printer. (BD)
02) "Distributed by" will be print on unit carton. (Production)
| 01) Done
| 01) May-26
02) June-26
| Muhammad Haris | 13/05/2026 | Muhammad Haris | 12/06/2026 |
|
| CMP-0064-26 | 13/05/2026 | Validation | Permanent | Major | Induction of detergent (RBS 705). | Currently, equipments are cleaned using treated water and rinse from hot purified water. | It is proposed to introduce RBS 705 in the cleaning process for production equipment and accessories along with hot water to improve removal of product residues and enhance cleaning effectiveness. | RA-0031-26-P | Approved | | In Progress | Pharma | 01) GRN of RBS 705 will be create. (WH)
02) Testing of RBS 705 will be performed. (QC)
03) RBS 705 will be released from SAP. (QC)
04) Analytical method will be developed and validation will be perform. (QC)
05) Swab and rinse recovery for analytical method will be perform. (QC)
06) Cleanibility and cleaning analytical method to be shared for wrost case product to determine residue limit within MACO. (PD)
07) List of worst identified product cleanibility to be shared. (PD)
08) Detergent qualification will be perform. QA(Val)
09) Cleaning validation will be performed for identified worst cases. QA(Val)
10) SOP will be developed for management of detergent RBS 705. (Production)
11) Log book will be prepared for reconciliation of RBS 705. (Production)
12) RBS 705 inventory will be manage. (Production)
|
|
| Muhammad Haris | 13/05/2026 | Muhammad Haris | 17/07/2026 |
|
| CMP-0065-26 | 25/05/2026 | SCM | Permanent | Minor | New Vendor induction. | We are purchasing Unit Carton, Direction Insert, Label, Catch Cover, Other secondary packaging materials from different suppliers. | It is proposed to procure Unit Carton, Direction Insert, Label, Catch Cover, Other secondary packaging materials also from new vendor M/s. Teamwork Packages (Pvt) Ltd. Located at 136-137, Korangi industrial area, sector 23, Karachi. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Vendor will be qualify based on onsite audit. (QA)
02) Approved vendor list will be update. (QA)
03) Supplier name will be added in SAP. (SCM)
04) Print proof and shade card will be approve. (QC)
|
| 01) June-26
02) July-26
03) Aug-26
04) Aug-26
| Muhammad Haris | 25/05/2026 | Muhammad Haris | 12/06/2026 |
|
| CMP-0066-26 | 25/05/2026 | SCM | Permanent | Major | Additional source induction of Vildagliptin. | We have approved sources for Vildagliptin as M/s Jiangxi Synergy, Fuxin Long Rui and Ms. Aparna Organics. | We intend to induct one more source M/s. Zhajiang Tianyu Pharmaceutical Co. Ltd No.15, Donghai 5th Avenue, Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone, Taizhou city, Zhejiang Province 317016, China. | N/A | Approved | 28/02/2027 | In Progress | Pharma | 01) Source approval document will be submitted to QA. (SCM)
02) Procurement of material from new source. (SCM)
03) Vendor list will be updated. (QA)
04) Source name will be added in SAP. (QA)
05) Process validation will be perform on three consecutive batches.
06) Stability will be perform on validation batches. (QC)
|
| 01) Aug-26
02) Oct-26
03) Aug-26
04) Aug-26
05) Feb-27
06) Feb-27
| Muhammad Haris | 25/05/2026 | Muhammad Haris | 12/06/2026 |
|
| CMP-0067-26 | 02/06/2026 | Production | Permanent | Moderate | Standardization of yield calculation and reconciliation in batch documents as per SOP No: PMG/2/084, Revision No: 02 | Currently, yield calculations are recorded in batch documents; however, theoretical yield, progressive yield and final packaging yield calculations are not fully aligned and standardized as per the requirements of SOP No: PMG/2/084. | It is proposed to align yield calculation practices in Batch Manufacturing Records (BMRs) and Batch Packaging Records (BPRs) with the requirements of SOP No: PMG/2/084. Theoretical yield and progressive yield shall be calculated, verified, and documented at each applicable stage of manufacturing. Final packaging yield shall be calculated based on total packed quantity, including QA retention/ sample packs and other approved quantities, in accordance with the approved SOP. | N/A | Approved | 31/12/2026 | In Progress | Pharma | 01) Batch documents (BMR and BPR) will be revise. (QA)
02) SOP of "Standardization of yield calculation and reconciliation in batch documents" (PMG/2/084) will be revise. (Production)
03) Training will be provided to concern person. (Production)
|
| 01) Dec-26
02) Aug-26
03) Aug-26
| Muhammad Haris | 02/06/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0068-26 | 02/06/2026 | Engineering | Permanent | Major | Replacement of G-01 door frames (Sol. Prep, Technical Area & Sieving) in General Pharma (Non-Ceph) Production floor. | Currently, door frames installed at the production floor Granulation-01 (Sol Prep Room, Sieving, Technical Room) of General Pharma (Non-Ceph) are in a damaged and rusted condition, which is not compliant with GMP standards. | Considering the above condition, it is hereby proposed to replace door frames at Granulation-01 (Sol Prep Room, Technical Area & Sieving) production area of General Pharma (Non-Ceph) with new MS door frames to ensure compliance with GMP standard. | RA-0028-26-P | Approved | 31/08/2026 | In Progress | Pharma | 01) All door frames of G-01 area will be replace with MS door frames. (Engineering)
02) Environmental monitoring will be perform. QC (Micro)
03) Smoke study will be perform. (Engineering)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
| Muhammad Haris | 02/06/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0069-26 | 04/06/2026 | PD | Permanent | Moderate | Change of coating material in Gouric 80mg and 40mg from in house coating formulation (sheffcoat PVA White 5Y01440, Quinoline Yellow and Lake Brilliant Blue) to ready-made Sheffcoat PVA Green 5Y04077. | Gouric 40mg & 80mg is being coated with Sheffcoat PVA White Quinoline Yellow and Lake Brilliant Blue Color during the coating process to achieve bright green color.
Existing color of Gouric 80mg is light green. | It is proposed to use Ready-made Sheffcoat PVA Green directly in the coating process.
It is proposed to use the same coating material of Gouric 80mg and 40mg. | RA-0032-26-P | Approved | | In Progress | Pharma | 01) PD trial documents required. (PD)
02) Accelerated and long term stability required of trial batch. (PD)
03) BOM will be revise in SAP. (QA)
04) Batch documents (BDR and BMR) will be revise. (QA)
05) Routing will be create in SAP. (Production)
06) Testing method will be revise. (QC)
07) Finish product specification will be update in SAP. (QC)
08) Process validation will be performed on three consecutive batches at coating stage. QA(Val)
09) Stability study will be perform on validation batches. (QC)
10) After manufacturing of validation batches SAP BOM will be revert to previous formulation. Previous version of batch documents will be effective again till three months stability results of validation batches. After three months stability results further decision will be made. (QA)
11) After testing of validation batches SAP specification for finished product will be revert back to previous specification. Previous version will be effective again till the three month stability result of validation batches. After the three months stability results further decision will be made. (QC)
12) Validation batches will be released after satisfactory three months stability. (QA)
13) Variation will be submitted in DRAP. (RA)
|
| 01) July-26
02) July-26
| Muhammad Haris | 04/06/2026 | Muhammad Haris | 17/07/2026 |
|
| CMP-0070-26 | 05/06/2026 | PD | Permanent | Major | Change in coating material for Evopride Plus 1/500mg tablet and Evopride 2/500mg tablet to resolve coating related challenge. | Currently, Sheffcoat White (5Y00625) is being used for both strengths of Evopride Plus tablets. During the coating stage, issues such as edge defects and shade variation have been observed in the finished tablets. | It is proposed to replace Sheffcoat White (5Y00625) with Sheffcoat PVA White (5Y01440) to improve the finished product appearance and to resolve the observed issues during the coating stage. | RA-0033-26-P | Approved | | In Progress | Pharma | 01) PD trial documents required. (PD)
02) Existing inventory of 200Kg Sheffcoat White (5Y00625) will be consume. (SCM)
03) BOM will be revise in SAP. (QA)
04) BDR and BMR will be revise. (QA)
05) Routing will be create in SAP. (Production)
06) Testing method will be revise. (QC)
07) Finish product specification will be update in SAP. (QC)
08) Process validation will be perform on three consecutive batches at coating stage. QA(Val)
09) Stability will be perform on validation batches. (QC)
10) Variation will be applied in DRAP. (RA)
|
| 01) Done
02) Jan-27
03) Jan-27
04) Jan-27
05) Jan-27
06) Jan-27
07) Jan-27
08) March-27
09) March-27
10)
| Muhammad Haris | 05/06/2026 | Muhammad Haris | 17/07/2026 |
|
| CMP-0071-26 | 05/06/2026 | Quality Assurance | Permanent | | Induction of New equipment refrigerator BPR-5V628 Bio-Base China in retention room General Pharma. | Currently, no refrigerator available in retention room General Pharma. | Induction of new equipment Refrigerator BPR-5V628 Bio-Base China in retention room General Pharma. | | Approved | | In Progress | Pharma | 01) DQ, IQ and OQ will be perform through vendor. QA(Val)
02) SOP will be prepare. (QA)
03) Training will be provided to concern person. QA(Val)
04) PQ will be perform. QA(Val)
05) Equipment list will be revise. QA(Val)
06) Calibration list will be update. QA(Val)
|
|
| Hamza Ahmed | 05/06/2026 | Muhammad Haris | 03/07/2026 |
|
| CMP-0072-26 | 08/06/2026 | PD | Permanent | Major | New launch product Tofacitinib 5mg tablet. | Product development activities of generic Tofacitinib 5mg tablet has been completed. | It is proposed to commercialize Tofacitinib 5mg tablet in PharmEvo facility. Batch size for Tofacitinib 5mg is 100,000 tablets (15Kg) | RA-0034-26-P | Approved | 31/10/2027 | In Progress | Pharma | 01) Trial documents required. (PD)
02) Stability study documents required. (PD)
03) Containment approach report is required. (PD)
04) Cleanibility report is required. (PD)
05) Technology transfer protocol (for process) is required. (PD)
06) Technology transfer protocol (for analytical) is required. (PD)
07) Registration letter is required. (RA)
08) Source approval documents will be submitted to QA. (SCM)
09) Procurement of Raw material. (SCM)
10) Artwork will be develop and approved. (BD)
11) Item code will be open for new develop artwork. (BD)
12) SFG and FG codes will be open. (SCM)
13) Procurement of packaging material. (SCM)
14) Analytical testing method will be prepare. (QC)
15) BOM will be create in SAP. (QA)
16) Batch documents (BDR, BMR and BPR) will be prepared. (QA)
17) Routing will be create in SAP. (Production)
18) Planning of product launch for commercial. (BD)
19) Process validation will be performed. QA(Val)
20) Hold time study will be perform. QA(Val)
21) Assessment will be perform for cleaning validation. QA(Val)
22) Product will be charge on stability study. (QC)
|
| 01) Done
02) Done
03) Aug-26
04) Aug-26
05) Sep-26
06) July-26
07) Aug-26
08) July-26
09) Oct-26
10) Sep-26
11) Sep-26
12) Aug-26
13) Oct-26
14) Nov-26
15) Dec-26
16) Dec-26
17) Dec-26
18) Dec-26
19) April-27
20) Oct-27
21) Aug-26
22) Aug-26
| Muhammad Haris | 08/06/2026 | Muhammad Haris | 27/07/2026 |
|
| CMP-0073-26 | 08/06/2026 | PD | Permanent | Major | New launch product Mirogablin 2.5mg, 5mg, 10mg and 15mg tablet. | Product development activities of generic Mirogabalin 2.5mg, 5mg, 10mg and 15mg tablet has been completed. | It is proposed to commercialize Mirogabalin 2.5mg, 5mg, 10mg and 15mg tablet in PharmEvo facility.
1) Batch size for Mirogabalin 2.5mg is 150,000 (15Kg)
2) Batch size for Mirogablin 5mg is 150,000 (15Kg)
3) Batch size for Mirogabalin 10mg is 100,000 tablet (20Kg)
4) Batch size for Mirogabalin 15mg is 50,000 tablet (15Kg) | RA-0035-26-P | Approved | 30/11/2027 | In Progress | Pharma | Mirogabalin 2.5mg Tablets, Mirogabalin 5mg Tablets and Mirogabalin 10mg Tablets and Mirogabalin 15mg Tablets:
01) Trial documents required. (PD)
02) Stability study documents required. (PD)
03) Containment approach report is required. (PD)
04) Cleanability approach report is required. (PD)
05) Technology transfer protocol (for process) is required. (PD)
06) Technology transfer protocol (for analytical) is required. (PD)
07) Registration letter is required. (RA)
08) Source approval documents will be submitted to QA. (SCM)
09) Procurement of raw material. (SCM)
10) Artwork will be develop and approved. (BD)
11) Item code will be open for new develop artwork (BD)
12) SFG and FG codes will be open. (SCM)
13) Procurement of packaging material. (SCM)
14) Blister tubes tooling will be procured for Mirogabalin 5mg tablets. (Production)
15) Analytical testing method will be prepare. (QC)
16) BOM will be create in SAP. (QA)
17) Batch documents (BDR, BMR and BPR) will be prepared. (QA)
18) Routing will be create in SAP. (Production)
19) Planning of product launch for commercial. (BD)
20) Process validation will be perform. QA (Val)
21) Hold time study will be perform. QA (Val)
22) Assessment will be perform for cleaning validation. QA (Val)
23) Product will be charge on stability study. (QC)
|
| 01) Done
02) Done
03) Aug-26
04) Aug-26
05) Sep-26
06) July-26
07) July-26
08) July-26
09) Nov-26
10) Aug-26
11) Aug-26
12) July-26
13) Sep-26
14)
15) Oct-26
16) Nov-26
17) Nov-26
18) Nov-26
19) Nov-26
20) May-27
21) Nov-27
22) Aug-26
23) Aug-26
| Muhammad Haris | 08/06/2026 | Muhammad Haris | 03/07/2026 |
|
| CMP-0074-26 | 08/06/2026 | BD | Permanent | Moderate | Revision of address on unit carton of Evopride 2mg in Vietnam. | Currently the following address is mentioned on the unit carton:
270A Lý Thu?ng Ki?t, P14, Q10, TPHCM
| It is proposed to add the following address as per distribution request.
270A Lý Thu?ng Ki?t, Phu?ng Diên H?ng, TP HCM | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Artwork will be develop and approve. (BD)
02) Item code will be open. (BD)
03) BOM will be update in SAP. (QA)
04) BPR will be update. (QA)
05) Specification will be update in SAP. (QC)
| 01) Done
02) Done
03) Done
| 01) June-26
02) June-26
03) June-26
04) Aug-26
| Muhammad Haris | 08/06/2026 | Muhammad Haris | 13/07/2026 |
|
| CMP-0075-26 | 08/06/2026 | RA | Permanent | | Change in tablet appearance (color differentiation) for Avsar Tablets 160/5mg and 160/10mg. | Currently, both Avsar 160/5mg and Avsar 160/10mg tablets have the same appearance, i.e., yellow-colored, oblong- shaped, film coated tablets with a bisect line on one side and plain on the other side. This similarity in appearance may lead to difficulty in visual identification of the two strengths. | Differentiate the tablet color of the two strengths as follows:
01) Avsar 160/5mg: Dark Yellow film-coated tablet. 02) Avsar 160/10mg: Light Yellow film-coated tablet. | N/A | Approved | | In Progress | Pharma | 01) PDR to be revised. (PD)
02) Batch documents will be revised. (QA)
03) FP specification will be revised. (QC)
04) LIMS/ SAP will be updated. (QC)
05) Stability protocol will be provided. (QC)
06) Validation protocol will be revised. /Justification letter will be provided. (Validation)
|
| 01) 12/06/2026
02) 12/06/2026
03) 12/06/2026
04) 12/06/2026
05) 12/06/2026
06) 12/06/2026
| Muhammad Haris | 08/06/2026 | Muhammad Haris | 22/06/2026 |
|
| CMP-0076-26 | 09/06/2026 | SCM | Temporary | | Use of U/C Zilero 2.5 mg 30's HM Packaging Material on BM-350 for Consumption of Remaining A/F and D/I Stock | Currently, we have A/F & D/I of Zilero 2.5mg tablet. 30's CP on BM-350 specs in inventory. | It is requested to use 1200004765 U/C Zilero 2.5mg 30s HM on BM-350 to consume remaining stock of A/F and D/I for one batch only. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 09/06/2026 | Muhammad Haris | 16/06/2026 |
|
| CMP-0077-26 | 22/06/2026 | BD | Permanent | | Implementation of Pharma Codes as per Hoonga Specifications. | Currently, the artworks used on the Hoonga Blister Machine do not include Pharma Code on the unit carton (U/C) and leaflet. | All existing artworks used on the Hoonga Blister Machine will be revised to include a pharma code on the unit carton (U/C) and leaflet on same item codes. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 22/06/2026 | | |
|
| CMP-0078-26 | 24/06/2026 | PD | Permanent | Major | Induction of "Sheffcoat PVA Green 5Y01077" from manufacturer "Kerry DO BRASIL LTDA". | Currently, Sheffcoat PVA Green 5Y01077 is not part of inventory. | It is proposed to induct and approve Sheffcoat PVA Green 5Y01077 from manufacturer "Kerry DO BRASIL LTDA". Address: ALAMEDA ARAPOEMA, 480-CENTRO EMPRESARINAL DE-TAMBORE-BARUERI-SAOPALO-BRASIL. | N/A | Approved | 31/12/2026 | In Progress | Pharma | 01) Source approval documents will be submitted to QA. (SCM)
02) Procurement of material from new source. (SCM)
03) New material code will be open. (SCM)
04) Vendor list will be updated. (QA)
05) Source name will be added in SAP. (QA)
06) Process validation will be performed. QA(Val)
07) Stability will be perform on validation batches. (QC)
|
| 01) July-26
02) Oct-26
03) July-26
04) Aug-26
05) Aug-26
06) Dec-26
07) Dec-26
| Muhammad Haris | 24/06/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0079-26 | 06/07/2026 | BD | Permanent | Major | Launch of Glyzemlina 10/5mg and Glyzemlina 25/5mg for Exphar in French West Africa. | The products mentioned below are not launched yet.
S.No: 01. Products: Glyzemlina 10/5mg. Generic: Empagliflozin + Linagliptin. Pack Szie: 4x7's. Shelf Life: 24months. Registration Timeline: Registered.
S.No: 02. Products: Glyzemlina 25/5mg. Generic: Empagliflozin + Linagliptin. Pack Szie: 4x7's. Shelf Life: 24months. Registration Timeline: Registered. | These products will be manufactured for Exphar and Exphar will market these products in French West Africa. These products will solely be manufactured for Exphar. | | Approved | | In Progress | Pharma | 01) Development and approval of artwork. (BD)
02) New item codes of packaging material will be open. (BD)
03) Specification of packaging material will be developed in SAP. (QC)
04) Procurement of packaging material. (SCM)
05) New item code of API will be open by mentioning the manufacturer name with API name. (SCM)
06) Procurement of API from approved source by Exphar. (SCM)
07) SFG and FG codes will be open. (SCM)
08) SFG and FG BOM will be create in SAP. (QA)
09) Batch documents (BDR, BMR, BYS and BPR) will be prepared. (QA)
10) Routing will be create in SAP. (Production)
11) Product launch in Exphar. (BD)
|
|
| Muhammad Haris | 06/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0080-26 | 06/07/2026 | BD | Permanent | Moderate | Shifting of Physician Samples of Srilanka to new standard tool on 2DT blister machine. | Physician Samples in Srilanka are being supplied either by cutting or folding the commercial blisters. | New standard tool for Physician Samples have been developed and currently marketed products of Srilanka will be shifted on the new tool. New Aluminium foils will be developed along with Unit Cartons and DI. | N/A | Approved | 30/09/2026 | In Progress | Pharma | 01) Artwork will be developed. (BD)
02) Item code will be open. (BD)
03) BOM will be revise in SAP. (QA)
04) Approval is required for additional pack size. (RA)
|
| 01) Sep-26
02) Sep-26
03) Sep-26
04) Sep-26
| Muhammad Haris | 06/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0081-26 | 07/07/2026 | Warehouse | Permanent | | Induction of New Logistics Service Provider. | Finished products are currently dispatched through TCS, LCS, M&P, T.M Cargo, Kinetic, Cargoline. | Induction of a new logistics service provider (MTN Transport Network) with temperature- controlled (below 25C) and dry vehicles. | | Under Approval | | | Pharma | 01) Updated administrative documents are required. (WH)
02) MTN transport network will be qualified based on onsite audit. (QA)
03) List of service provider will be updated. (QA)
04) Transport route profile will be required. (WH)
05) Transport validation will be performed by conducting 3 runs on seasonal verification. QA(Val)
06) Calibration will be performed for all sensors. QA(Val)
|
|
| Muhammad Haris | 07/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0082-26 | 07/07/2026 | Warehouse | Permanent | | Change the name of Kinetic Logistics to Kinetic Business Solution. | Kinetic logistics transportation invoices & CN were previously issued under Kinetic Logistics accounts. | Effective immediately, all FTL (Full Truck Load) operations will be processed exclusively through the Kinetic Logistics account. All invoices & CN for FTL services will be issued in the name of Kinetic Business Solutions. | | Under Approval | | | Pharma | 01) Updated administrative documents are required. (WH)
02) Kinetic business solution will be qualified based on onsite audit. (QA)
03) List of service provider will be updated. (QA)
|
|
| Muhammad Haris | 07/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0083-26 | 14/07/2026 | BD | Permanent | Moderate | Launch of S-GLP (Semaglutide) injections in local market through contract manufacturing. | S-GLP (Semaglutide) injections are not launched in the local market yet:
Brand Name: S-GLP 0.25mg/0.188ml. Generic Name: Semaglutide. Dosage Form: Injection. Strength: 0.25mg/0.188ml. Pack Size (CP): 1's. Name of Contract Manufacturer: Ferozsons Laboratories Limited.
Brand Name: S-GLP 0.5mg/0.375ml. Generic Name: Semaglutide. Dosage Form: Injection. Strength: 0.5mg/0.375ml. Pack Size (CP): 1's. Name of Contract Manufacturer: Ferozsons Laboratories Limited.
Brand Name: S-GLP 1mg/0.75ml. Generic Name: Semaglutide. Dosage Form: Injection. Strength: 1mg/0.75ml. Pack Size (CP): 1's. Name of Contract Manufacturer: Ferozsons Laboratories Limited. | S-GLP (Semaglutide) injections are planned for launch in the local market through Contract Manufacturing. | N/A | Approved | 31/01/2027 | In Progress | Pharma | 01) Manufacturer onsite audit will be conducted. (QA)
02) Registration is required. (RA)
03) Development of artwork. (BD)
04) Artwork will be reviewed, approved and share with manufacturer. (BD)
05) FG code will be open. (SCM)
06) Planning of product launch through contract manufacturing. (BD)
07) SMF, Reference standard, testing method and MOA will be required from manufacturer. (QA)
08) List of contract manufacturing will be updated. (QA)
09) Outsource testing of the product will be conducted. (QC)
| 01) Done
02) Done
03) Done
04) Done
05) Done
| 01) Done
02) Done
03) Aug-26
04) Aug-26
05) July-26
06) Dec-26
07) Done
08) Dec-26
09) Jan-27
| Muhammad Haris | 14/07/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0084-26 | 14/07/2026 | QC | Permanent | Minor | Addition of Disintegration Test in Finished Product Specification | Currently, Disintegration Test is performed in IPC at core stage but it is not part of finished product testing method. | It is proposed to include the disintegration test in the finished product specifications. The test will not be a part of the finished product release specification; however, it will be performed on every manufactured batch and the results will be documented in the corresponding raw data records. | | Under Approval | | | Pharma | 01) Testing method will be revise. (QC)
02) Finish product specifications will be revised in SAP. (QC)
03) For PV batches QC will provide raw data and their results to validation. (QC)
|
|
| Muhammad Haris | 14/07/2026 | Muhammad Haris | 28/07/2026 |
|
| CMP-0085-26 | 14/07/2026 | RA | Permanent | Moderate | Update the existing artwork of Arbi-H 150/12.5mg, 300/12.5mg and 300/25mg tablets in Srilanka. | The generic name on existing artwork of Arbi-H 150/12.5mg, 300/12.5mg and 300/25mg tablets in Srilanka is not aligned as per the guideline on labelling of medicine dated (15/10/2019) by NMRA. | The Generic Name of the artworks for Arbi-H 150/12.5mg, 300/12.5mg and 300/25mg tablets will be updated to meet the labelling requirements as per guideline on labelling of medicine dated (15/10/2019) issued by National Medicine Regulatory (NMRA), Srilanka | N/A | Approved | 30/11/2026 | In Progress | Pharma | 01) Registration is required. (RA)
02) Artwork will be developed and approved. (BD)
03) Item codes will be open for new developed artwork. (BD)
04) Artwork will be reviewed as per NMRA guideline. (RA)
05) BOM will be revise in SAP. (QA)
06) BPR will be prepared. (QA)
|
| 01) Nov-26
02) Sep-26
03) Sep-26
04) Sep-26
05) Nov-26
06) Nov-26
| Muhammad Haris | 14/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0086-26 | 16/07/2026 | BD | Permanent | Minor | Change in Direction Insert of Erli Plus XR Tab 12.5/1000mg 4X7's already launched in Iraq. FG Code: 1400000629 | The current DI for Erli Plus XR Tab. 12.5/1000mg 4X7's Iraq (Item Code: 1200002537) contains prescribing information for only a single strength. | Replace the exisiting DI with a new harmonized DI (Item Code:12000003894) that includes prescribing information for all strengths of Erli Plus XR tablets. | N/A | Approved | 31/07/2026 | In Progress | Pharma | 01) Artwork will be developed. (BD)
02) Item code will be opened. (BD)
03) BOM will be revised in SAP. (QA)
|
| 01) Done
02) Done
03) July-26
| Muhammad Haris | 16/07/2026 | Muhammad Haris | 24/07/2026 |
|
| CMP-0087-26 | 16/07/2026 | Production | Permanent | | Increase in batch size of Xcept 2.5mg tablet. | Currently, batch size of Xcept 2.5mg tablet is 10.00Kg (100,000) tablets. | It is proposed to increase the batch size of Xcept 2.5mg tablet from 10.00kg (100,000) tablets to 30.00Kg (300,000) tablets.
S.No: 01. Product Name: Xcept 2.5mg tablet. Current Batch Size (Kg): 10.00Kg. Proposed Batch Size (Kg): 30.00Kg. Equipment: G2, ZP37 (B1 & BII), T-700 and Conventional Coating Pan 24. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 16/07/2026 | Muhammad Haris | 16/07/2026 |
|
| CMP-0088-26 | 20/07/2026 | SCM | Permanent | Major | Additional source induction of API: Budesonide, Formoterol Fumarate Dihydrate and Tiotropium Bromide Monohydrate for DPI | We are currently procuring API: Budesonide, Formoterol Fumarate Dihydrate & Tiotropium Bromide Monohydrate for DPI from M/S Vamsi Labs Ltd., India. | We intend to induct one more source for all 3 APIs M/S. Shandong Risen-Sun Pharmaceutical Co., Ltd No. 3577 of Peitianmen Street, Tai'an High-Tech Industrial Development Zone, Shandong Province China. | N/A | Approved | 31/01/2027 | In Progress | Pharma | 01) Source approval documents will be submitted to QA. (SCM)
02) Procurement of material from new source. (SCM)
03) Vendor list will be updated. (QA)
04) Source name will be added in SAP. (QA)
05) Process validation will be performed. QA(Val)
06) Stability will be performed on validation batches. (QC)
|
| 01) Aug-26
02) Oct-26
03) Sep-26
04) Sep-26
05) Jan-27
06) Jan-27
| Muhammad Haris | 20/07/2026 | Muhammad Haris | 27/07/2026 |
|
| CMP-0089-26 | 21/07/2026 | SCM | Permanent | Moderate | Institution Order for Karachi Port Trust (KPT). | Order of Karachi Port Trust (KPT) received, which requires to supply stock in Green printed commercial pack. | We have received an order of following products:
Product: Gouric 40mg Tablet 20’s Inst Green. Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 20’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
Product: Inosita Plus 50/500mg Tablet 28’s Inst Green Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 28’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
Product: Lowplat 75mg Tablet 10’s Inst Green. Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 10’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
Product: Lowplat Plus 75/75mg Tablet 10’s Inst Green. Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 10’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
Product: Nise 100mg Tablet 20’s Inst Green. Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 20’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
Product: X-Plended 5mg Tablet 10’s Inst Green. Aluminum Foil: Commercial Foil. Unit Carton: Green Pack of 10’s. Printing Requirements: BOMs will be opened using the commercial foil and packed in the special green printed commercial pack.
The order is to be supplied using the above-mentioned artwork and pack sizes.
The same aluminum foil as used for the commercial products will be utilized. However, green unit cartons with the same commercial artwork will be required for packing.
| N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Artwork for unit carton will be developed. (BD)
02) Item code for unit carton will be opened. (BD)
03) FG code will be opened. (SCM)
04) BOM will be created in SAP. (QA)
05) BPR will be prepared. (QA)
06) Packaging specifications will be created in SAP. (QC)
|
| 01) Aug-26
02) Aug-26
03) July-26
04) Aug-26
05) Aug-26
06) Aug-26
| Muhammad Haris | 21/07/2026 | Muhammad Haris | 27/07/2026 |
|
| CMP-0090-26 | 22/07/2026 | BD | Permanent | Moderate | Addition of SKU of Physician Sample of Erli Plus XR Tab. 25/1000mg PS 1x1's in Pakistan. | Physician Sample of only two SKU of Erli Plus XR Tab. available.
1. Erli Plus XR Tab. 5/1000mg 2's
2. Erli Plus XR Tab. 12.5/1000mg 2's | Addition of SKU of Physician Sample of Erli Plus XR Tab. 25/1000 PS 1x1's for pakistan market. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) Artwork of unit carton will be developed. (BD)
02) Item code of unit carton will be opened. (BD)
03) FG code will be opened. (SCM)
04) BOM will be create in SAP. (QA)
05) BPR will be prepared. (QA)
06) Packaging specifications will be create in SAP. (QC)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Aug-26
06) Aug-26
| Muhammad Haris | 22/07/2026 | Muhammad Haris | 27/07/2026 |
|
| CMP-0091-26 | 23/07/2026 | Warehouse | Permanent | Moderate | Modification of Warehouse Labelling Procedure by Use of Reusable Acrylic and Stainless Steel Plates. | Current governing SOP: WHG/2/010, covering receiving, dispensing, storage, and packaging-material issuance, and applicable to Ceph, Non-Ceph, and Nutraceutical warehouses.
We are using different paper labels for every stage.
•In dispensing/sampling room: In process/Status , undercleaning, cleaned , under maintainance.
•In cages: In process/Status , undercleaning, cleaned
•In balances: undercleaning, cleaned labels are used | •Room Status: Acrylic plates will be installed for write-and-wipe use.
•Cages Status: Stainless steel plates will be attached to the cages with the cage identification number. A viewing window will also be added to display ___ of ___, allowing easy recognition of how many cages are being used in the batch.
•Balance Status: The balance status will be maintained on a stainless steel plate fixed to the wall or back area where the balance is placed.
Note: SOP version no. will not mention on acrylic and S.S plate only SOP number will be mentioned and this statement also reflect of sop that (Version no is not mentioned on acrylic plate) while revise
•Utensil Labeling: The current labeling procedure will remain the same. Stainless steel trays and identification hooks will continue to be maintained in the utensils room. | N/A | Approved | 30/09/2026 | In Progress | Pharma | 01) New reusable acrylic and stainless steel plates/ labels will be designed and information will be provided. (WH)
02) New reusable acrylic and stainless steel plates/ labels will be procured and installed in designated area i.e (Dispensing room/ booth, cage/ container and walls/ back area where the balance is placed. (Engineering/ WH)
03) SOP will be prepared for use of Acrylic plate. (WH)
04) SOP will be prepared for use of stainless steel. (WH)
05) SOP of “Cleaning of Dispensing/ Sampling Booth & Filters” (WHG/5/036) will be revised. (WH)
06) Traing will be provided to concern person. (WH)
|
| 01) Aug-26
02) Sep-26
03) Aug-26
04) Aug-26
05) Aug-26
06) Aug-26
| Muhammad Haris | 23/07/2026 | Muhammad Haris | 11/08/2026 |
|
| CMP-0092-26 | 27/07/2026 | BD | Permanent | Modderate | Change of Packaging artwork for Actiflor Sachet 250mg (Myanmar) | The existing artwork for Actiflor Sachet 250mg (Myanmar) states the storage condition as: "Store below 30C." | Based on the stability study, the product stability has been established at 25C. Therfore, the storage condition on the packaging artwork will be revised to:
"Store below 25C." | N/A | Approved | | In Progress | Pharma | 01) Artwork will be developed. (BD)
02) Item code will be opened. (BD)
03) Existing inventory will be write off. (SCM)
04) BOM will be revise in SAP. (QA)
05) Packaging specifications will be updated in SAP. (QC)
|
| 01) Done
02) Done
03)
04)
05)
| Muhammad Haris | 27/07/2026 | Muhammad Haris | 11/08/2026 |
|
| CMP-0093-26 | 27/07/2026 | SCM | Permanent | Moderate | Change in manufacturer name and site. | We have approved manufacturer by name of A.R Packages, Address: House# L-359 Sector 4 Rehmania Town North Karachi. | It is proposed that manufacturer has changed their name to A.R Packages Private Limited and site to a new facility which is located at Plot no. A/SITE Area Nooriabad Jamshoro Kotri, Sindh. | N/A | Approved | 30/09/2026 | In Progress | Pharma | 01) Updated administrative documents required. (SCM)
02) Vendor on-site audit will be performed. (QA)
03) Vendor list will be updated. (QA)
04) New supplier code will be opened. (SCM)
05) Old code will be blocked for procurement. (SCM)
|
| 01) Sep-26
02) Sep-26
03) Sep-26
04) Sep-26
05) Sep-26
| Muhammad Haris | 27/07/2026 | Muhammad Haris | 11/08/2026 |
|
| CMP-0094-26 | 29/07/2026 | QC | Permanent | Major | Implementation of Auto-Calculation in HPLC and UV Software for Assay, Content Uniformity and Dissolution Testing. | Currently, the calculation of analytical results for assay, content uniformity and dissolution tests is performed using the SAP/LIMS software after completion of testing activities. The chromatographic data generated by the UV and HPLC system is manually transcribed to SAP/LIMS for calculation and reporting of results. | It is proposed to implement the HPLC and UV software's auto-calculation function for assay, content uniformity and dissolution testing.-
1. Shimadzu HPLC: LabSolution software
2. Agilent HPLC: Control Panel software
3. Thermo HPLC: Chromeleon software
4. Shimadzu UV 1800: UV Probe software
| | Approved | 30/09/2026 | In Progress | Pharma | 01) Excel sheet validation will be performed. (QC)
02) Three batches will be selected for verification of each HPLC software (Chromeleon, Lab Solution and Control Panel) auto calculation. (QC)
03) Three batches will be selected for verification of the UV spectrophotometer software (UV Probe) auto calculation. (QC)
04) SOP will be prepared. (QC)
05) Training will be provided to concern person. (QC)
|
| 01) Sep-26
02) Sep-26
03) Sep-26
04) Sep-26
05) Sep-26
| Muhammad Haris | 29/07/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0095-26 | 31/07/2026 | PD | Permanent | Major | Addition of new four HPLCs systems in PD Analytical Laboratory. | The PD analytical laboratory currently has 10 HPLC system installed to support the testing of new products, trial batches, raw materials, comparative dissolution profile (CDP) studies, stability studies and analytical method validation.
S.No: 01. Instrument Name: HPLC. Quantity: 10. Make: Shimadzu/ Water/ Thermo Scientific. | The PD analytical laboratory has expanded its analytical capacity by adding four new HPLC systems to meet the increasing analytical workload and project requirements.
S.No. 01. Instrument Name: HPLC. Quantity: 4. Make: Shimadzu/ Thermo Scientific. | N/A | Approved | 30/09/2026 | In Progress | Pharma | 01) IQ and OQ of all instruments will be perform. (PD)
02) SOP of all instruments will be prepared and training will be provided to concern person. (PD)
03) PQ of all instruments will be performed. (PD)
04) Instrument list will be updated. (PD)
|
| 01) Sep-26
02) Sep-26
03) Sep-26
04) Sep-26
| Muhammad Haris | 31/07/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0096-26 | 31/07/2026 | SCM | Permanent | Moderate | Institution order for DGH, Punjab (Lowplat 75mg) 2026-2027 | An order received from the DGH, Punjab, requiring the supply of stock in both green commercial packaging and green bulk boxes.
Product Code: 1400000237. Product: Lowplat Tab. 75mg CP Inst. Gr DGH 1x10's. Institute: DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 1x10 pack is not compatible with the Hoonga m/c and in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machine.
Product Code: 1400000683. Product: Lowplat Tab. 75mg CP RIC Inst Green 100x10's. Institute:RIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 100x10 pack is in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machine.
Product Code: 1400000238. Product: Lowplat Tab. 75mg CP Inst. 100x10's PIC. Institute: PIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 100x10 pack is in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machine.
Product Code: 1400000675. Product: Lowplat Tab. 75mg CP FIC Inst Green 100x10's. Institute: FIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 100x10 pack is in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machine.
Product Code: 1400000641. Product: Lowplat Tab. 75mg CP CPEIC Inst. 10x100's. Institute: CPEIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 100x10 pack is in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machine.
Product Code: 1400001104. Product: Lowplat Tab. 75mg CP WIC Inst. 100x10's. Institute: WIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: Existing green 100x10 pack is in black text with the government stamp. Aluminium Foil: The existing A/F is not compatible with the Hoonga machin | We are anticipating order of following product in different phases and pack sizes:
Product Code: 1400000237. Product: Lowplat Tab. 75mg CP Inst. Gr DGH 1x10's. Institute: DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required (Green commercial pack 1x10's with white text. Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: Code Required. Product: Lowplat Tab. 75mg CP Inst. Gr DGH 100x10's. Institute: DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: 1400000683. Product: Lowplat Tab. 75mg CP RIC Inst Green 100x10's. Institute: RIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: 1400000238. Product: Lowplat Tab. 75mg CP Inst 100x10's PIC. Institute: PIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: 1400000675. Product: Lowplat Tab. 75mg CP FIC Inst Green 100x10's. Institute: FIC DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: 1400000641. Product: Lowplat Tab. 75mg CP CPEIC Inst. 100x10's. Institute: CPEIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp.
Product Code: 1400001104. Product: Lowplat Tab. 75mg CP WIC Inst. 100x10's. Institute: WIC- DGH. Printing Requirements: BOM needs to be changed. Unit Carton: New code required of Green bulk box (10x100's) with white text with Govt. Stamp, after consuming current inventory of 1200002902 (2,312 bulk boxes). Aluminium Foil: New Code Required: A new printed A/F code is required for the Hoonga machine, featuring "Punja Govt.- Not for Sale" in both english and urdu, along with the official government stamp. | N/A | Approved | 30/09/2026 | In Progress | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) Old inventory will be consumed. (SCM)
05) BOM will be created in SAP. (QA)
06) BPR will be prepared. (QA)
07) Specifications will be updated in SAP. (QC)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Sep-26
06) Sep-26
07) Sep-26
| Muhammad Haris | 31/07/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0097-26 | 31/07/2026 | SCM | Temporary | Minor | Consumption of Cold Formable Foil 238mm Self-Printed (1200000413). | Cold Formable Foil 238mm Self-Printed was previously used. After a new Cold Formable Foil was introduced, the old foil was no longer used and the remaining stock 1300Kg is still available in inventory. | It is proposed to consume the available inventory of Cold Formable Foil 238mm Self-Printed in production on Hoonga blister machines, as it is compatible with the existing packaging process. The attached list of products identifies the item for which this foil will be utilized. | N/A | Approved | 31/08/2026 | In Progress | Pharma | 01) SCM will intimate QA for the revision of BOM. (SCM)
02 BOM will be revise in SAP. (QA)
03) POI will be revised. (QA)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
| Muhammad Haris | 31/07/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0098-26 | 11/08/2026 | Production | Permanent | Major | Batch size upgradation for Zibes 10mg tablet from 10kg to 100Kg batch size. | The current batch size is 10Kg, which is manufactured using the DCB 30KG. the process is proposed to be shifted to the V-Blender area to increase the batch size from 10Kg to 100Kg. | S.No: 1. Product Name: Zibes 10mg tablet. Current Batch Size (Kg): 10Kg. Proposed Batch Size (Kg): 100Kg. Equipment: V- Blender.
All the other sections remains the same. | | Approved | 31/01/2027 | In Progress | Pharma | 01) FG and SFG code will be opened. (SCM)
02) SFG and FG BOM will be created in SAP. (QA)
03) Routing will be created in SAP. (Production)
04) Batch documents (BDR and BMR) will be revised. (QA)
05) Process validation will be performed on three consecutive batches. (QC)
06) Stability will be performed on validation batches. (QC)
07) Validation will be applied in DRAP. (RA)
|
| 01) Aug-26
02) Sep-26
03) Sep-26
04) Sep-26
05) Dec-26
06) Dec-26
07) Jan-27
| Muhammad Haris | 11/08/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0099-26 | 11/08/2026 | PD | Permanent | Major | New launch product Ibuprofen/ Paracetamol 200/500mg tablet. | Product development activities of generic Ibuprofen/ Paracetamol 200/500mg tablet has been completed. | It is proposed to commercialize Ibuprofen/ Paracetamol 200/500mg tablet in Pharmevo facility. Batch Size for Ibuporfen/ Paracetamol 200/500mg is 300,000 tablets (270.00Kg) | | Approved | 31/07/2027 | In Progress | Pharma | 01) Trail documents required. (PD)
02) Stability study documents required. (PD)
03) Containment approach report is required. (PD)
04) Cleanibility report is required. (PD)
05) ADE value to be procured. (PD)
06) Technology transfer protocol (for process) is required. (PD)
07) Technology transfer protocol (for analytical testing) is required. (PD)
08) Registration is required. (RA)
09) Source approval documents will be sumitted to QA. (SCM)
10) Procurement of raw material. (SCM)
11) Artwork will be develop and approved. (BD)
12) Item code will be open for new develop artwork. (BD)
13) FG code will be opened. (SCM)
14) Procurement of packaging material. (SCM)
15) Packaging specification will be developed in SAP/ LIMS. (QC)
16) Analytical testing method will be prepared. (QC)
17) Finish product specification will be developed in SAP/ LIMS (QC)
18) BOM will be create in SAP. (QA)
19) Batch documents (BDR, BMR and BPR) will be prepared. (QA)
20) Routing will be create in SAP. (Production)
21) Planning of product launch for commercial. (BD)
22) Process Validation will be performed. QA (Val)
23) Stability study will be performed on validation batches. (QC)
24) Hold Time Study will be performed QA (Val)
25) Cleaning validation will be performed. QA(Val)
|
| 01) Done
02) Done
03) Nov-26
04) Nov-26
05) Nov-26
06) Nov-26
07) Nov-26
08) Nov-26
09) Nov-26
10) Feb-27
11) Nov-26
12) Nov-26
13) Nov-26
14) Jan-27
15) Mar-27
16) Mar-27
17) Mar-27
18) Mar-27
19) Mar-27
20) Mar-27
21) Mar-27
22) May-27
23) May-27
24) July-27
25) May-27
| Muhammad Haris | 11/08/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0100-26 | 12/08/2026 | BD | Permanent | Moderate | Addition of registration numbers of Honduras and Nicaragua on artworks of Erli Plus XR 12.5/1000mg tablets in Central America. | The registration numbers of Honduras and Nicaragua are not added on unit carton and foil of Erli Plus XR 12.5/1000mg tablets in Central America. | The registration numbers of Honduras and Nicaragua will be added on unit carton and foil of Erli Plus XR 12.5/1000mg Tablets in Central America. The existing inventory of unit carton and foil will be utilized first. | N/A | Approved | 31/10/2026 | In Progress | Pharma | 01) Artwork will be developed (U/C and Foil). (BD)
02) Item code will be opened (U/C and Foil). (BD)
03) Existing inventory will be consumed. (SCM)
04) BOM will be revise in SAP. (QA)
05) Packaging specification will be update in SAP. (QC)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
04) Aug-26
05) Oct-26
| Muhammad Haris | 12/08/2026 | Muhammad Haris | 21/08/2026 |
|
| CMP-0101-26 | 12/08/2026 | BD | Permanent | Major | Launch of products for Dawa Limited in Kenya. | The products mentioned below are not launched yet.
S.No. 1. Products: Empaflo Trio XR 10/5/1000mg Tablets. Generic: Empagliflozin+ Linagliptin+ Metformin. Pack Size: 5x7's. Shelf Life: 24 months. Launch Quantities for 1st Order: 4 Batches (5,716 Packs). Launch Timelines: Dec-26.
S.No. 1. Products: Empaflo Trio XR 25/5/1000mg Tablets. Generic: Empagliflozin+ Linagliptin+ Metformin. Pack Size: 5x7's. Shelf Life: 24 months. Launch Quantities for 1st Order: 1 Batch (4,300 Packs). Launch Timelines: Dec-26.
S.No. 1. Products: Nephix 10mg Tablets. Generic: Finerenone. Pack Size: 3x10's. Shelf Life: 24 months. Launch Quantities for 1st Order: 1 Batch (5,000 Packs). Launch Timelines: Dec-26.
S.No. 1. Products: Nephix 20mg Tablets. Generic: Finerenone. Pack Size: 3x10's. Shelf Life: 24 months. Launch Quantities for 1st Order: 1 Batch (5,000 Packs). Launch Timelines: Mar-27. | These products will be manufactured for Dawa Limited and Dawa Limited will market these products in Kenya. These products will solely be manufactured for Dawa Limited. | N/A | Approved | 31/03/2027 | In Progress | Pharma | 01) Registration letter required. (RA)
02) Product launch for Dawa Limited. (BD)
03) Development and approval of artwork. (BD)
04) New item code will be open. (BD)
05) FG code will be open. (SCM)
06) BOM will be create in SAP. (QA)
07) BPR will be prepared. (QA)
08) Procurement of packaging material. (SCM)
09) Specification will be developed in SAP. (QC)
10) Variation will be submitted. (RA)
|
| 01) Nov-26
02) March-27
03) Aug-26
04) Aug-26
05) Aug-26
06) March-27
07) March-27
08) Based on Export Order
09) March-27
10) Done
| Muhammad Haris | 12/08/2026 | Muhammad Haris | 21/08/2026 |
|
| CMP-0102-26 | 13/08/2026 | SCM | Permanent | Moderate | Institution order of RIC, DGHP | Order of Rawalpindi Institute of Cardiology (RIC-DGHP) received, which requires to supply stock in Green printed commercial pack. | Product Code: New code required. Product: Zibes Tab. 10mg CP Inst. Gr DGH 1x20's. Aluminium Foil: A new printed A/F code is required, featuring "Punjab Govt- Not for Sale" in both English and Urdu in red, along with the official government stamp in green. Unit Carton: New code required Green commercial pack (1x20's) with white text with Govt. Stamp. Product Code: New code required. Product: Telsarta Tab. 40mg CP Inst. Gr DGH 1x10's. Aluminium Foil: A new printed A/F code is required, featuring "Punjab Govt- Not for Sale" in both English and Urdu in red, along with the official government stamp in green. Unit Carton: New code required Green commercial pack (1x10's) with white text with Govt. Stamp. Product Code: New code required. Product: Ramipace Tab. 5mg CP Inst. Gr DGH 2x14's. Aluminium Foil: A new printed A/F code is required, featuring "Punjab Govt- Not for Sale" in both English and Urdu in red, along with the official government stamp in green. Unit Carton: New code required Green commercial pack (1x14's) with white text with Govt. Stamp. Product Code: 1400001411. Product: Xcept Tab. 20mg Inst. RIC 2x7's. Aluminium Foil: A new printed A/F code is required, featuring "Punjab Govt- Not for Sale" in both English and Urdu in red, along with the official government stamp in green. Unit Carton: 1200004570 U/C Xcept 20mg Tab. Inst. RIC 14's | N/A | Approved | 31/10/2026 | In Progress | Pharma | 01) Development and approval of artwork. (BD)
02) Item code will be open. (BD)
03) FG code will be open. (SCM)
04) BOM will be created in SAP. (QA)
05) BPR will be prepared. (QA)
06) Packaging specifications will be updated in SAP. (QC)
|
| 01) Aug-26
02) Aug-26
03) Aug-26
04) Sep-26
05) Sep-26
06) Oct-26
| Muhammad Haris | 17/08/2026 | Muhammad Haris | 21/08/2026 |
|
| CMP-0103-26 | 18/08/2026 | QC | Permanent | | Revision of finished product specification for Gouric Tablet 40mg and Gouric Tablet 80mg from In-House method to Japanese Pharmacopoeia Specifications. | Currently, Gouric 40mg and 80mg tablet are being tested against the existing In-Housse specifications. | It is proposed to replace the existing In-House specification of Gouric 40mg tablet and Gouric 80mg tablet with the applicable current JP specifications. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 18/08/2026 | | |
|
| CMP-0104-26 | 19/08/2026 | PD | Permanent | Major | Replacement of existing coating formulation with Ready-Made Opadry II Green 85F210163. | Iron Oxide Yellow and Lake of Indigo Carmine are used as colorants in the PVA based coating formulation (i.E. Instamoist shield White Aqua II or Opadry White II 85G68918) for the commercial products including Inosita Plus XR 50/1000mg tablets, X-Plended EZ 20/10mg tablets and Erlina 10/5mg tablets. | It is proposed to replace the existing coating formulation with the ready-made coating material "Opadry II Green 85F210163" for the above mentioned products. The proposed activity was performed for Inosita Plus XR 50/1000mg tablets, and the results were found to be satisfactory. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 19/08/2026 | | |
|
| CMP-0105-26 | 21/08/2026 | Production | Permanent | | The slugging process of Klevra 250mg tablets was obsoleted from granulation process by approved innovation for granulation process. | Currently, Klevra 250mg tablet are manufactured through a slugging process followed by granulation. | As a part of process optimization, the slugging step is proposed to eliminated from the manufacturing process of Klevra 250mg tablets. | | Approved | | | Pharma | 01) BMR will be revised. (QA)
02) Process validation will be performed on three consecutive batches. QA(Val)
03) Stability will be charged on validation batches. (QC)
04) Variation will be applied in DRAP. (RA)
|
|
| Muhammad Haris | 21/08/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0106-26 | 21/08/2026 | SCM | Permanent | | Development of new master carton (FG-04) for Export. | Currently, multiple master cartons (MC-02, MC-08, MC-09, MC-18, MC-20, MC-21, and MC-22) are used for export shipments as specified respective BOMs. After packing the products into these master cartons are further packed into Finished Goods (FG) cartons in the warehouse prior to dispatch. | A new Master Carton (FG-04) has been developed with improved grammage & strength and a standardized size that is suitable for use with the all export products. the new FG-04 will be packed in production floor & will serve as the final shipping carton, eliminating the requirement for additional packing into FG cartons before dispatch. | | | | | Pharma |
|
|
| Muhammad Haris | 24/08/2026 | Muhammad Haris | 24/08/2026 |
|
| CMP-0107-26 | 24/08/2026 | SCM | Permanent | | New vendor induction. | We are purchasing aluminium foil from M/s. N.J Enterprises, M/S. Allied Trading & Printing & M/s. Prism Gravure. | It is proposed to procure aluminium foil also from new vendor M/s. The Printing Company. Located at B-333, Sector 6-G, Mehran Town, Korangi Industrial Area, Karachi. | | | | | Pharma |
|
|
| Muhammad Haris | 24/08/2026 | Muhammad Haris | 24/08/2026 |
|
| CMP-0108-26 | 24/08/2026 | BD | Permanent | | Launch of Erli 10mg tab through Tender in Central America. | Erli 10mg tab is not launched through Tender in Central America. | Erli 10mg Tab is planned for launch in Central America through Tender. | | | | | Pharma |
|
|
| Muhammad Haris | 24/08/2026 | | |
|
| CMP-0109-26 | 25/08/2026 | Production | Permanent | Major | Addition and installation of Honga 600P Blister Machine and Reallocation of Existing Blister Machines in Blister Area. | Currently, eight blister cubicles are available in the blister section, with the following machines installed: Blister Cubicle: Blister No. 1 . Installed Machine: Hoonga-A. Blister Cubicle: Blister No. 2. Installed Machine: Hoonga-B. Blister Cubicle: Blister No. 3. Installed Machine: 2DT. Blister Cubicle: Blister No. 4. Installed Machine: BM350-A. Blister Cubicle: Blister No. 5. Installed Machine: BM350-D. Blister Cubicle: Blister No. 6. Installed Machine: BM350-E. Blister Cubicle: Blister No. 7. Installed Machine: BM350-B. Blister Cubicle: Blister No. 8. Installed Machine: BM350-C. The products mentioned in the attached list are currently being blistered on the BM-350 and 2DT machines using the existing dimensions as follows: 01) BM-350: A/F _ 266mm and CFF_ 268mm. 02) 2DT: A/F - 170mm and CFF - 175mm. | It is proposed to add and install a new honga 600P blister machine in the blister section for blistering of products currently running on 2DT and BM-350 machines, as per the specified dimensions (List attached): A/F - 288mm and CFF - 290mm. The list of applicable products proposed for transfer to the Honga 600P machine is attached. The following machine reallocation is also proposed: 01) The existing 2DT machine is installed at Blister No. 3 will be shifted to Blister No. 8. 02) The existing BM-350C machine installed at Blister No. 8 will be relocated to the DPI Area. 03) The new honga 600P machine will be installed at blister no. 3. The proposed machine relocation and product transfer will be carried out in accordance with approved procedures and applicable qualification/ validation requirements. | | | | | Pharma |
|
|
| Muhammad Haris | 25/08/2026 | | |
|
| CMP-0110-26 | 25/08/2026 | SCM | Permanent | | Institutional Order for Nawaz Sharif Institute of Cardiology Samli Muree (NSCC-Samli Muree). | Order of NSCC received, which require to supply stock in Green Packing with Govt. of Punjab Printed Foil. | We have received order of following product: Xcept Tab. 20mg CP 2X7'S
Order needs to be provided with the below-mentioned artwork and pack size details.
For Aluminum Foil:
Foil with Govt. of Punjab logo & “Govt of Punjab Property – Not for Sale” (in English & Urdu).
For Box:
Green Color box of commercial pack size, with Govt. of Punjab logo & “Govt of Punjab Property – Not for Sale” (in English & Urdu). like Normal Commercial Box, Traceable GTIN. | | | | | Pharma |
|
|
| Muhammad Haris | 25/08/2026 | Muhammad Haris | 25/08/2026 |
|
| CMP-0111-26 | 27/08/2026 | SCM | Permanent | | Chnage in manufacturer site. | We have approved manufacturer by name of M/S Anwar Packages. Address: A-26, Saima Villas, Block B, North Nazimabad, Karachi. | It is proposed that manufacturer has changed their manufacturing site to Plot no. 47 Ramzan Goth, Sector-16, Gulshan e Bahar, Orangi town Near Karachi Ijtemagah, Karachi. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 27/08/2026 | | |
|
| CMP-0112-26 | 27/08/2026 | Production | Permanent | | Revision of BMR thickness range for Dapwiz 10mg Tablets and Fasteso 40mg Tablets. | Currently, we are manufacturing Dapwiz 10mg Tab & Fasteso 40mg Tab with BMR thickness ranges as:
01) Dapwiz 10mg Tab (3.30mm to 4.30mm)
02) Fasteso 40mg Tab (3.00mm to 3.60mm) | It is proposed to further shrink the BMR thickness range as per Feeder Tubes thickness which is as:
01) Dapwiz 10mg Tab (3.60mm to 4.00mm)
02) Fasteso 40mg Tab (3.20mm to 3.40) | | | | | Pharma |
|
|
| Muhammad Haris | 27/08/2026 | | |
|
| CMP-0113-26 | 27/08/2026 | Production | Permanent | Major | Addition of new coating machine (Model: FC-170) in production General Pharma. | New Coating Machine (Model: SFC-170) has been procured for Production General Pharma. | It is proposed to add new Coating Machine (Model: SFC-170) in newly developed coating cubicle no. 5 in the Production General Pharma. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 27/08/2026 | Muhammad Haris | 03/09/2026 |
|
| CMP-0114-26 | 27/08/2026 | Production | Permanent | Major | Addition of Kalian E 380 Compression Machine in Production General Pharma. | Kalian E-380 compression has been procured for Production General Pharma. | It is proposed to add newly procured Kalian E-380 Compression Machine in compression cubicle no. 3 in the Production General Pharma. | | | | | Pharma |
|
|
| Muhammad Haris | 27/08/2026 | Muhammad Haris | 03/09/2026 |
|
| CMP-0115-26 | 01/09/2026 | BD | Permanent | | Launch of new products in Myanmar | Products mentioned below are not launched in Myanmar yet.
S.No: 1. Products: Exalis 2.5mg Tablets. Generic: Apixaban. Pack Size: 3x10's. Shelf Life: 24months. Registration: Registered.
S.No: 2. Products: Exalis 5mg Tablets. Generic: Apixaban. Pack Size: 3x10's. Shelf Life: 24months. Registration: Registered. | These products are planned for launch in Myanmar. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 01/09/2026 | | |
|
| CMP-0116-26 | 02/09/2026 | Production | Permanent | Major | Final blending of following products to be perform in DCB 400Kg in blending 01 area non-ceph pharma. | The attached list of products are manufactured in DCB 400Kg in granulation 01 area needs to be processed in DCB 400Kg/ Blending 01 area. | The products included in the attached list will be manufactured in DCB 400Kg in blending 01 area. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 02/09/2026 | Muhammad Haris | 03/09/2026 |
|
| CMP-0117-26 | 03/09/2026 | PD | Permanent | Major | New launch product Fluticasone Furoate/ Umeclidinium/ Vilanterol 200/62.5/25mcg & 100/62.5/25mcg DPI Capsule. | Product development activities of generic Fluticasone Furoate/ Umeclidinium/ Vilanterol 200/62.5/25mcg & 100/62.5/25mcg DPI capsule has been completed. | It is proposed to commercialize Fluticasone Furoate/ Umeclidinium/ Vilanterol 200/62.5/25mcg & 100/62.5/25mcg DPI capsule in pharmevo facility. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 03/09/2026 | | |
|
| CMP-0118-26 | 03/09/2026 | Production | Permanent | | Shifting of Lowplat Plus 75mg Tablet (Inner) on the T-700 Compression Machine. | Currently, Lowplat Plus 75mg Tablet (Inner) has been validated on the ZP37B & Fette-P 3030 Compression Machines. | It is proposed to shift Lowplat Plus 75mg Tablet (Inner) on the T-700 Compression Machine. | | | | | Pharma |
|
|
| Muhammad Haris | 03/09/2026 | | |
|
| CMP-0119-26 | 04/09/2026 | QA | Temporary | | Addition of suffix “A” or “B” in batch numbers of FWA products. | The same products are marketed in French West Africa (FWA) with different shelf life. For example, Inosita Plus 50/500mg tablets are marketed with shelf life of both 24 months and 36 months.
Recently, a query was raised by an FWA customer regarding the receipt of the same product with different shelf life under the same batch number. To ensure proper traceability and differentiation between the products having different shelf life, separate FG codes have already been created. The FG code suffix FWA-A is assigned to the product with a 24 months shelf life, whereas FWA-B is assigned to the product with a 36 months shelf life.
| It is proposed to embossed/ print the suffix “A” with the batch number for products having FG code FWA-A, and the suffix “B” with the batch number for products having FG code FWA-B on both Blister and Unit Carton.
For Example:
Inosita Plus 50/500mg Tab FWA-A= 6J005A
Inosita Plus 50/500mg Tab FWA-B= 6J005B
| | Under Approval | | | Pharma |
|
|
| Hamza Ahmed | 04/09/2026 | Muhammad Haris | 09/09/2026 |
|
| CMP-0120-26 | 07/09/2026 | QA | Permanent | Minor | Change in Date Format on Batch Release Certificate (BRC). | Currently, we have Date, Month and Year in Batch Release Certificate. | It is proposed to change the format to Month and year on Batch Release Certificate. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 07/09/2026 | Muhammad Haris | 09/09/2026 |
|
| CMP-0121-26 | 08/09/2026 | BD | Permanent | Minor | Change of Direction Insert in Erli Tab 10mg and 20mg in Cambodia. | Currently, following D/I is being used in Erli Tab 10mg and 20mg Cambodia.
1400001268: Erli Tab. 10mg CP (CMB) 14's.
1200003990: D/I Erli 10mg Tab. KSV
1400001269: Erli Tab. 25mg CP (CMB) 14's
1200003990: D/I Erli 25mg Tab. KSV | It is proposed to change replace the D/I with the following mentioned code.
1200004314: D/I Erli Tab. Ranges EXGPB. | N/A | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 08/09/2026 | | |
|
| CMP-0122-26 | 10/09/2026 | Engineering | Permanent | | Revamping of existing Non-Ceph manufacturing plant by constructing new Dispensing area 5 Nos. These areas will be constructed in existing 40ft packaging material warehouse and the same will be connected with existing non ceph mfg. area. | Currently we have 2 Nos. Dispensing Areas, both are operating in 02 shifts operation. Both are not fulfilling the production demand/ volumes. | It is proposed to increase the number of dispensing areas to meet the production demand /volumes.
As the existing secondary packaging material warehouse is shifted to new centralized warehouse, so it is proposed to utilize that area to add the additiuonal dispensing areas.
Following are the construction activates are planned:
1) Convert 40ft secondary packaging warehouse in 05 Nos. new dispensing areas.
2) 2 Nos. dispensing areas developed for low RH NMT 35%.
3) 3 Nos. dispensing areas developed for RH NMT 65%.
4) Staging area for dispensed material cages.
5) Office for production.
6) Dispensing washing & Utensils store.
7) New change room to enter in the dispensing area.
8) Engineering workshop. | | Under Approval | | | Pharma |
|
|
| Muhammad Haris | 10/09/2026 | Muhammad Haris | 10/09/2026 |
|
| CMP-0123-26 | 10/09/2026 | SCM | Temporary | | Utilization of U/C Nise Tab 100mg 20s INST Rv00 received on 300gms Bux Board. | All institutional Unit Cartons are currently procured on 300gms Bleach Board. | M/s. Al-Afzal Graphics has supplied 1200005291 U/C Nise Tab 100mg 20s INST Rv00 on 300gms Bux Board instead of 300gms Bleach board. It is proposed to consume this lot (170000003969) for one time only. | | | | | Pharma |
|
|
| Muhammad Haris | 10/09/2026 | Muhammad Haris | 11/09/2026 |